WO2011102906A1 - Imageable lipid-oil-water nanoemulsion delivery system - Google Patents
Imageable lipid-oil-water nanoemulsion delivery system Download PDFInfo
- Publication number
- WO2011102906A1 WO2011102906A1 PCT/US2011/000314 US2011000314W WO2011102906A1 WO 2011102906 A1 WO2011102906 A1 WO 2011102906A1 US 2011000314 W US2011000314 W US 2011000314W WO 2011102906 A1 WO2011102906 A1 WO 2011102906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoemulsion
- lipid
- oil
- imaging
- imaging agent
- Prior art date
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 222
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 124
- 238000003384 imaging method Methods 0.000 claims abstract description 73
- 239000012216 imaging agent Substances 0.000 claims abstract description 71
- 230000001413 cellular effect Effects 0.000 claims abstract description 7
- 150000002632 lipids Chemical class 0.000 claims description 146
- 210000004027 cell Anatomy 0.000 claims description 132
- 239000002245 particle Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 66
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 59
- -1 indium-I l l Chemical compound 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 59
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 25
- 229930182558 Sterol Natural products 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 235000003702 sterols Nutrition 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 23
- 235000012000 cholesterol Nutrition 0.000 claims description 19
- 235000019197 fats Nutrition 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000265 homogenisation Methods 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 235000000346 sugar Nutrition 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 150000007513 acids Chemical class 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 230000008901 benefit Effects 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 150000003432 sterols Chemical class 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 9
- 210000003463 organelle Anatomy 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000003613 bile acid Substances 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- DLWLXTLRGQWGPC-UHFFFAOYSA-N 10,13-dimethyl-17-[1-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]propan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2CC(O)CCC2(C)C(CCC23C)C1C3CCC2C(C)CNC1=CC=C([N+]([O-])=O)C2=NON=C12 DLWLXTLRGQWGPC-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000090 biomarker Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000002600 positron emission tomography Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000004700 cellular uptake Effects 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 238000000527 sonication Methods 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000010166 immunofluorescence Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 239000003586 protic polar solvent Substances 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 235000019487 Hazelnut oil Nutrition 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019774 Rice Bran oil Nutrition 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 239000010477 apricot oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 239000010468 hazelnut oil Substances 0.000 claims description 2
- 239000010460 hemp oil Substances 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000008164 mustard oil Substances 0.000 claims description 2
- 239000002018 neem oil Substances 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000003346 palm kernel oil Substances 0.000 claims description 2
- 235000019865 palm kernel oil Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000008171 pumpkin seed oil Substances 0.000 claims description 2
- 239000008165 rice bran oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- 150000005691 triesters Chemical class 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 210000001163 endosome Anatomy 0.000 claims 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 238000011013 endotoxin removal Methods 0.000 claims 2
- 238000009928 pasteurization Methods 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- DVUWFIWQOSNKQJ-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one;sodium Chemical compound [Na].[Na].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 DVUWFIWQOSNKQJ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 claims 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 claims 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 229910052693 Europium Inorganic materials 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- XEEYBQQBJWHFJM-AKLPVKDBSA-N Iron-59 Chemical compound [59Fe] XEEYBQQBJWHFJM-AKLPVKDBSA-N 0.000 claims 1
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 claims 1
- BUGBHKTXTAQXES-AHCXROLUSA-N Selenium-75 Chemical compound [75Se] BUGBHKTXTAQXES-AHCXROLUSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 claims 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- GUTLYIVDDKVIGB-YPZZEJLDSA-N cobalt-57 Chemical compound [57Co] GUTLYIVDDKVIGB-YPZZEJLDSA-N 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims 1
- 230000002542 deteriorative effect Effects 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- KBQHZAAAGSGFKK-NJFSPNSNSA-N dysprosium-165 Chemical compound [165Dy] KBQHZAAAGSGFKK-NJFSPNSNSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- UYAHIZSMUZPPFV-NJFSPNSNSA-N erbium-169 Chemical compound [169Er] UYAHIZSMUZPPFV-NJFSPNSNSA-N 0.000 claims 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 238000005243 fluidization Methods 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 229940006110 gallium-67 Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 claims 1
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 claims 1
- 238000002786 image-guided radiation therapy Methods 0.000 claims 1
- 230000000266 injurious effect Effects 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- DNNSSWSSYDEUBZ-OIOBTWANSA-N krypton (81mKr) gas Chemical compound [81Kr] DNNSSWSSYDEUBZ-OIOBTWANSA-N 0.000 claims 1
- 229960001299 krypton (81mkr) gas Drugs 0.000 claims 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 229950009740 molybdenum mo-99 Drugs 0.000 claims 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 claims 1
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 229940097886 phosphorus 32 Drugs 0.000 claims 1
- 230000008884 pinocytosis Effects 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- ZLMJMSJWJFRBEC-AKLPVKDBSA-N potassium-42 Chemical compound [42K] ZLMJMSJWJFRBEC-AKLPVKDBSA-N 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- IGLNJRXAVVLDKE-AHCXROLUSA-N rubidium-81 Chemical compound [81Rb] IGLNJRXAVVLDKE-AHCXROLUSA-N 0.000 claims 1
- KJTLSVCANCCWHF-BKFZFHPZSA-N ruthenium-106 Chemical compound [106Ru] KJTLSVCANCCWHF-BKFZFHPZSA-N 0.000 claims 1
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 claims 1
- PUZPDOWCWNUUKD-ULWFUOSBSA-M sodium;fluorine-18(1-) Chemical compound [18F-].[Na+] PUZPDOWCWNUUKD-ULWFUOSBSA-M 0.000 claims 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 claims 1
- 229940006509 strontium-89 Drugs 0.000 claims 1
- CIOAGBVUUVVLOB-RNFDNDRNSA-N strontium-92 Chemical compound [92Sr] CIOAGBVUUVVLOB-RNFDNDRNSA-N 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims 1
- 238000001429 visible spectrum Methods 0.000 claims 1
- 229940106670 xenon-133 Drugs 0.000 claims 1
- NAWDYIZEMPQZHO-AHCXROLUSA-N ytterbium-169 Chemical compound [169Yb] NAWDYIZEMPQZHO-AHCXROLUSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 67
- 230000001594 aberrant effect Effects 0.000 abstract description 14
- 230000037356 lipid metabolism Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 description 44
- 229940079593 drug Drugs 0.000 description 35
- 210000004881 tumor cell Anatomy 0.000 description 28
- 238000011282 treatment Methods 0.000 description 23
- 230000004044 response Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 229940011411 erythrosine Drugs 0.000 description 12
- 235000012732 erythrosine Nutrition 0.000 description 12
- 239000004174 erythrosine Substances 0.000 description 12
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000005284 excitation Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 6
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 6
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 6
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 208000021039 metastatic melanoma Diseases 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 150000001841 cholesterols Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- AHNXVAQNMFHKPJ-VEIPTCAHSA-N (3r,8s,9s,10r,13r,14s,17r)-3-azido-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C=C2C[C@H](N=[N+]=[N-])CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AHNXVAQNMFHKPJ-VEIPTCAHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- QSVJYFLQYMVBDR-UHFFFAOYSA-N Ergosterin Natural products C1C(O)CCC2(C)C3=CCC4(C)C(C(C)C=CC(C)C(C)C)CCC4C3=CC=C21 QSVJYFLQYMVBDR-UHFFFAOYSA-N 0.000 description 1
- JFGPCUKCLGXBGS-UHFFFAOYSA-N FC1=NN1 Chemical compound FC1=NN1 JFGPCUKCLGXBGS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- BXEFQPCKQSTMKA-UHFFFAOYSA-N OC(=O)C=[N+]=[N-] Chemical compound OC(=O)C=[N+]=[N-] BXEFQPCKQSTMKA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000004279 Oxytocin receptors Human genes 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical class Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- YQYYDLWKDGKMKI-UHFFFAOYSA-N cholestatrienol Natural products C1C(O)CCC2(C)C3=CCC4(C)C(C(C)CCCC(C)C)CCC4C3=CC=C21 YQYYDLWKDGKMKI-UHFFFAOYSA-N 0.000 description 1
- 102000049842 cholesterol binding protein Human genes 0.000 description 1
- 108010011793 cholesterol binding protein Proteins 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- QSVJYFLQYMVBDR-CMNOFMQQSA-N dehydroergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]4C3=CC=C21 QSVJYFLQYMVBDR-CMNOFMQQSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid group Chemical class C(CCCCCCC\C=C\CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- WTOSNONTQZJEBC-UHFFFAOYSA-N erythrosin Chemical compound OC(=O)C1=CC=CC=C1C(C1C(C(=C(O)C(I)=C1)I)O1)=C2C1=C(I)C(=O)C(I)=C2 WTOSNONTQZJEBC-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- JOUDBUYBGJYFFP-FOCLMDBBSA-N thioindigo Chemical compound S\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2S1 JOUDBUYBGJYFFP-FOCLMDBBSA-N 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0078—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion microemulsion, nanoemulsion
Definitions
- This invention relates to therapeutic and diagnostic agents, and more particularly to a lipid-oil-water nanoemulsion suitable for introduction into a patient and capable of promoting both active selective agent concentration into cells characterized by aberrant lipid metabolism, including but not limited to tumor cells, and imaging and/or treatment of a primary or metastatic tumor formed by such cells.
- RECIST Solid Tumors
- Measurement and response is determined by comparative measurements of the most recent imaging results to measurements taken at time of diagnosis or at baseline prior to entering a clinical trial. Staging of disease may also taking into account alternative imaging techniques such as positron emission tomography (PET) using radiolabelled glucose, ultrasound, or imaging using radiolabelled antibodies which target tumor specific antigens. A complete response is disappearance of all target lesions, while a partial response is a 30% decrease in the sum of the longest diameter of target lesions. Progressive disease is a 20% increase in the sum of the longest diameter of target lesions and/or the appearance of new tumors. Stable disease is considered to be small changes that do not meet the above criteria. To limit of detectability can affect interpretation of results as swelling of tumors can occur leading to an enlarged image even as tumor cells are responding to drug. Attempts to improve RECIST methodology include validating for clinical trial acceptable methods to incorporate volumetric three-dimensional anatomical imaging and the use of dynamic contrast imaging.
- anatomical imaging has been fundamental to the evaluation of patients receiving drugs that are cytotoxic and expected to shrink tumors. It has been assumed not only that early determination of tumor shrinkage may potentially spare patients from experiencing those debilitating side effects accompanying chemotherapy but also that tumor shrinkage would correlate well with longer term survival. What has emerged in retrospective studies, however, is not only that tumor shrinkage may not always correlate well with longer term survival but also that metastatic disease as well as local relapse can contribute to disease-related death. Additionally, not all patients may respond to a drug at the same rate or in the same way. Furthermore, the emergence of new drugs with novel mechanisms of action has made the use of anatomical imaging questionable as an indicator for tumor response to drug.
- a drug has been found to be cytostatic
- patients who would have been characterized under RECIST as having stable disease or a slowed trajectory of disease progression have gone on to achieve longer term survival than those patients receiving cytotoxic agents who would be considered responders under RECIST.
- some drugs are able to help cancer be "managed" so that patients bearing tumors may nevertheless enjoy longer life expectancy and better life quality.
- An additional confounding consideration for REC1ST is that with some targeted therapies, the drug-related mechanism of tumor cell death can influence what appears in an anatomical image and vary with time of treatment.
- the dissolution and shrinkage of tumors is part of the final steps in a complicated cascade of cellular and sub- cellular local and immune system changes as a response to therapy.
- tumor swelling, edema, and inflammation can occur, phenomena which may suggest tumor enlargement or growth on an anatomical image.
- Such effects make the timing of taking the image, the kinetics of these effects, and the resolution of these effects critical.
- contrast agents and additional imaging methods may help better elucidate both what is occurring within the tumor and the kinetics thereof, in many situations an imaging center may lack the expertise, equipment, or resources to accurately reach the proper interpretation of the tumor image presented.
- Targeted molecular imaging of cancer in combination with an anatomical imaging modality permits a physician to characterize a cancer mass' biological properties accurately and ultimately to select the treatment most likely to be effective based on the tumor's characteristics.
- Conventional imaging modalities which often use additional contrast agents administered to the patient to enhance the quality of the images generated; these contrast agents often differ by the imaging modality used, and each contrast agent demonstrates different inherent strengths and limitations, such as toxicity.
- radiolabeled agents include 18-fluorodeoxyglucose (FDG) to measure metabolic activity of cancer cells versus normal cells, or radiolabeled nucleotides to measure cellular proliferation.
- FDG 18-fluorodeoxyglucose
- PET imaging has its shortfalls: the technique requires exposure to radiation, and some drugs may alter the ability for the radiolabelled agent to be taken up intracellularly without killing the tumor cells at a rate that is consistent with what appears on image. Additionally, false positives can occur on inflammation and invasion of tumors with infiltrating lymphocytes, or even on healing and fibrosis. Given these shortfalls, the ability to utilize molecular targeted ligands that are specific for cancer cells is therefore extremely important so as to enable distinguishing true disease response or progression from artifact.
- molecularly-targeted isotopes can be delivered to specific targets within a cancer cell, concentrating cell-killing doses of radiation directly to a tumor mass, thereby decreasing radiation exposure to healthy tissue.
- Lipid-soluble drugs readily penetrate cell membranes and may be transported through cells.
- Cells characterized by hyperproliferation, such as cancer cells generally exhibit an aberrant lipid metabolism, marked by their greatly-increased preferential uptake of lipids and fatty acids. Indeed, it is not uncommon for cancer patients to present with low or depleted levels of serum lipids, including cholesterol.
- Upregulation of lipid receptors as well as changes in plasma membrane lipid raft compositions have been suggested to be associated with diverse solid tumor cell types and increased lipid uptake.
- lipids have been found to play essential roles in membrane structure, growth and metastasis, signal transduction, and transport processes.
- EPR enhanced permeability and retention
- lipid-based nanoparticles or HDL- or LDL-based drug carriers that mimic the natural receptor ligand and increase targeting and drug uptake into cancer cells have been prepared with various therapeutic agents, however, optimized formulations for the promotion of active tumor cell drug uptake, especially agents for the imaging of cancer, have been lacking.
- fluorescent dyes have relatively only recently been explored for their capability to act as targeted molecular imaging agents for cancer. While many classes of highly fluorescent organic compounds are known, over the past two decades dyes from the difluoro-boraindacene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) family (BODIPY) have been recognized as a photostable substitute for fluorescein.
- BODIPY difluoro-boraindacene
- BODIPY inherent photophysical properties, including excellent thermal and photochemical stability relative to fluorescein; high fluorescence quantum yield; negligible triplet-state formation and nanosecond excited-state lifetimes; intense absorption profile and large absorption coefficients; narrow emission profiles; good solubility; relative insensitivity to changes in polarity and pH; and large range of colors have all added to the general attractiveness of these fluorophore materials.
- BODIPY-based dyes have thus been designed for and used as biological labelling reagents, with most current labelling studies involving the use of commercial materials bearing an anchor with which to attach the dye to the biological host.
- DiO 3,3'-dioctadecyloxacarbocyanine perchlorate
- Eosin Y an acidic fluorescent red dye
- Eosin Y is a tetrabromo derivate of fluorescein used to stain basic parts of the cell, such as cytoplasm, collagen, red blood cells, and muscle fibers, for examination under the microscope.
- Eosin is most often used as a counterstain to Hematoxylin in H&E (Hematoxylin and Eosin) staining.
- H&E Hematoxylin and Eosin
- Eosin Y is typically used in concentrations of 1 to 5 percent weight by volume, dissolved in water or ethanol; a small concentration (0.5 percent) of acetic acid usually gives a deeper red stain to the tissue.
- Erythrosine B the disodium salt of 2,4,5,7-tetraiodofluorescein, is used as a cherry-pink biological stain and a radiopaque medium with a maximum absorbance at 530 nm in an aqueous solution. Because Erythrosine B is identical in structure to Eosin Y except that iodine is substituted for the bromines at each position on Eosin Y, Erythrosine B is often used as a substitute for Eosin Y staining.
- the stain Rose Bengal (4,5,6,7-tetrachloro-2',4 , ,5 , ,7'-tetraiodofluorescein) is a nontoxic dye whose sodium salt is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby identify damage to the eye.
- This fluorescent stain has also been studied for its separate property as having a therapeutic effect on metastatic melanoma.
- 26 target lesions in eleven metastatic melanoma patients were directly injected with 10% w/v Rose Bengal in saline at a dose of 0.5 ml/cc lesion volume, with twenty-eight additional untreated lesions observed for potential bystander effect.
- labelled cholesterol-derived sterols have been formulated in the past to be used to study the metabolism and intracellular localization of cholesterol, including a variety of photoreactive, spin-labelled, and fluorescent cholesterol analogues.
- photoreactive, spin-labelled, and fluorescent cholesterol analogues See, e.g., Gimpl G and Gehrig-Burger (2007). Cholesterol reporter molecules. Biosci. Rep. 27:335-358, herein incorporated by reference.
- these analogues possess all of the properties of the parental cholesterol molecule, these molecules have been reported to localize in cholesterol-enriched microdomains.
- Photoreactive cholesterol probes such as cholesteryl diazoacetate; 3a-azido-5-cholestene; 3a- (4-azido-3-iodosalicylic)-cholest-5-ene; p-azidophenacyl 3a-hydroxy-5P-cholan-24-ate; 25- azidonorcholesterol; sterols with diazoacetate, aryldiazirines or fluorodiazirine attached at C- 22 or C-24; [ 3 H]22-(p-benzoylphenoxy)-23,24-bisnorcholan-5-en-3p-ol; and [ 3 H]6-azi-5a- cholestanol (i.e., photocholesterol) and [ 3 H]7-azi-5a-cholestanol have been used to visualize the nicotinic acetylcholine receptor and oxytocin receptors and may be used to identify and analyze other putative cholesterol binding proteins at the molecular level
- fluorescent cholesterol analogues which are distinguished between those analogues which possess intrinsic fluorescence (e.g., dehydroergosterol and cholestatrienol) and those in which a fluorophore or photoreactive group is attached (e.g., NBD-cholesterol, BODIPY-cholesterol, and dansyl-cholestanol).
- Such technology has also been used to analyze the potential efficacy of cholesterol- utilizing agents in the treatment of cancer.
- VIP vasoactive intestinal peptide
- SSL sterically stabilized liposomes
- researchers covalently inserted VIP into BODIPY-cholesterol-labelled SSL and then incubated rat breast cancer tissue sections in vitro with the liposomes .
- LCMs gas- or air-filled lipid coated microbubbles
- the production process for LCMs is based on simple mechanical shaking of an aqueous suspension of nonionic lipids, such as saturated glycerides and cholesterol esters, of specific chain lengths and in a fixed ratio. In all cases, the majority of lipids added (99%) flocculate or precipitate with additional loss of material on filtration with yields less than 1%. Still, these artificial LCMs were found to be very long-lived, lasting over 6 months in vitro.
- LCMs are sufficiently small and pliable enough to pass across the fenestrated capillary walls of tumor-tissue microcirculation.
- there has not been an efficacious formulation of a targeted molecular imaging agent utilizing LCM technology which presents minimal to nonexistent levels of adverse side effects upon patient administration.
- production methods are complex and small changes in conditions can result in significant differences in particle size and performance features.
- Typical approaches include high-shear homogenization and ultrasound, high-pressure homogenization, hot homogenization, cold homogenization, and solvent emulsification evaporation. Sterilization by aseptic filtration or radiation may also be complex. Thus, attempts to increase drug payload and solubility of lipids in LCMs with addition of a drug in ethanol and aqueous solution followed by high-shear homogenization result in the formation of poorly-stable non- gas-containing particles that contain little if any drug.
- Lipid-oil-water nanoemulsions have also been described and prepared in the art. (See, e.g. , US Patent 7387790 to Shorr et al. ; Constantinides PP, Chaubal MV, and Shorr R (2008). Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev 60:757-67; and Barbarese E, Ho SY, D'Arrigo JS, and Simon RH (1995). Internalization of microbubbles by tumor cells in vivo and in vitro. J Neurooncol 26:25-34, all incorporated by reference.) Stability was achieved by modification of conditions of high shear homogenization. To date, however, there has not been an efficacious formulation of a targeted molecular imaging agent using lipid-oil-water nanoemulsion technology which presents minimal to nonexistent levels of adverse side effects upon patient administration.
- Administering imaging agents with an appropriate delivery vehicle that simultaneously promotes accumulation and cellular internalization in a cancer mass but limits accumulation in healthy tissues to promote accurate imaging of the cancer mass is highly desirable. With more efficient delivery, systemic and healthy tissue concentrations of imaging agents may be reduced while achieving the same or better imaging results with fewer or diminished side effects. Further, a delivery vehicle that would not be limited to a single type of cancer but would allow for selective accumulation into a cancer mass and cellular internalization into diverse cancer cell types would be especially desirable and allow for safer more effective treatment of cancer. A delivery vehicle that would also allow for elevated loading capacity for the imaging agent would be a significant advance in the art.
- a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which exhibits rapid and increased selective and preferential uptake into tumor cells.
- the present invention broadly provides a stable lipid-oil- water nanoemulsion that demonstrates dramatically increased and selective uptake and concentration into the cytosol of diseased, injured, or mutated cells of warm-blooded animals, including humans, compared to healthy cells.
- the disease, injury, or mutation is characterized by aberrant lipid metabolism, and in a more preferred embodiment of the present invention, the disease is cancer.
- the lipid-oil- water nanoemulsion is comprised of lipid particles as hereinafter defined, uniformly dispersed through homogenization in an aqueous phase capable of being selectively and preferentially internalized within a diseased cell, including a cancer cell; an effective amount of at least one pharmaceutically-acceptable imaging agent associated with the lipid nanoemulsion; and a pharmaceutically-acceptable carrier or excipient therefor.
- the lipid particles each comprise at least one non-bilayer-forming lipid, among which the imaging agent is physically or chemically integrated.
- Such suitable lipid particles have been found to enhance significantly the targeted delivery and concentration of an associated payload into diseased cells characterized by aberrant lipid metabolism, including cancer cells.
- the nanoemulsion exhibits exceptional physical and chemical stability for an extended duration of time, thereby greatly facilitating prepackaging of the nanoemulsion in stable, ready-to-administer forms.
- the imaging agent may be a fluorescent dye, such as, but not limited to, BODIPY, DiO, Rose Bengal, Eosin Y, and Erythrosine B.
- the imaging agent may be a labelled sterol, such as, but not limited to, BODIPY-cholesterol, NBD-cholesterol, and dansyl-cholesterol, and their associated cholesteryl esters.
- the imaging agent is radiolabelled, such as, but not limited to, 14 C-cholesterol.
- any component of the nanoemulsion of the present invention e.g., the lipid particles or the labelled moiety
- FIGURE 1 illustrates data demonstrating that the uptake of the lipid nanoparticles of the present invention is directly proportional to their concentration.
- FIGURE 2 shows data demonstrating that the uptake of the lipid nanoparticles of the present invention is a function of time.
- FIGURE 3 depicts data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in colon tumor-derived cell lines.
- FIGURE 4 portrays data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in breast tumor-derived cell lines.
- FIGURE 5 illustrates data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in central nervous system tumor-derived cell lines.
- FIGURE 6 depicts data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in lung tumor-derived cell lines.
- FIGURE 7 illustrates the results of an experiment to determine to the amount of uptake of the lipid-oil-water nanoemulsion of the present invention where one component of the nanoemulsion is systematically deleted from the final composition.
- FIGURE 8 shows the results of an experiment to determine to the amount of uptake of the lipid-oil-water nanoemulsion of the present invention where one component of the nanoemulsion is mixed 1 : 1 with cholesterol to form the lipid nanoparticles administered to the cells.
- the present invention is generally directed to a stable lipid-oil-water nanoemulsion that demonstrates dramatically increased and selective uptake and concentration into the cytosol of diseased, injured, or mutated cells in warm-blooded animals compared to healthy cells.
- warm-blooded animals include those of the mammalian class, such as humans, horses, cattle, domestic animals including dogs and cats, and the like, subject to disease, injury, mutation, and other pathological conditions and syndromes.
- the disease, injury, or mutation is characterized by aberrant lipid metabolism, and in a more preferred embodiment of the present invention, the disease is cancer.
- the nanoemulsion is comprised of lipid particles as hereinafter defined, uniformly dispersed through homogenization in an aqueous phase capable of being selectively and preferentially internalized within a cell characterized by aberrant lipid metabolism, including a cancer cell; an effective amount of at least one pharmaceutically- acceptable imaging agent associated with the lipid nanoemulsion; and a pharmaceutically- acceptable carrier or excipient therefor, thereby making the lipid particles particularly well- suited for the selective delivery to and effective concentration within such diseased cells and tissues as tumorous ones.
- the lipid particles of the nanoemulsion are structured to facilitate both elevated passive accumulation and active internalization into diseased cells and tissues, including tumor cells and tissues.
- the lipid particles are taken into these cells through active metabolic uptake as they passively accumulate in the vascular area of the diseased tissue.
- the lipid particles of the present invention provide a delivery vehicle selectively and preferentially targeted for uptake and internalization by cells characterized by aberrant lipid metabolism, including tumor and cancer cells.
- Internalization as used herein means that the lipid particles are actively taken up by the cell.
- the lipid particles of the nanoemulsion are exceptionally physically and chemically stable over an extended period of time and hence experience minimal loss of imaging or therapeutic capability due to undesirable precipitation, aggregation, or insolubility that is typically exhibited in delivery systems in the prior art. Moreover, these lipid particles display other favorable characteristics including controlled release; enhanced drug stability; positive drug loading capacity; better compatibility with hydrophobic drugs; relatively low biotoxicity; and low organic solvent content. The lipid particles are also relatively simple and convenient to prepare and to administer.
- lipid particle is meant to encompass any lipid-containing structures, typically nanosized, which are at least substantially-intact particles forming part of a nanoemulsion.
- substantially-intact means that the particles maintain their shape in the absence of a membrane, as contrasted with a liposome.
- the lipid particles are comprised of at least one non-bilayer-forming lipid.
- a lipid bilayer structure or arrangement is typically formed by certain kinds of lipids having a hydrophilic end (polar head region) and a hydrophobic end (nonpolar tail region), including amphipathic molecules such as phospholipids, which exhibit the ability and/or tendency to self-organize into two opposing layers of lipid molecules in aqueous solution.
- the two opposing layers of lipid molecules are arranged so that their hydrophobic ends face one another to form an oily core, while their hydrophilic ends face the aqueous solutions on either side of the bilayer structure.
- the term "non-bilayer-forming lipid” encompasses a lipid that lacks such ability and/or tendency to form a lipid bilayer structure or arrangement in an aqueous environment.
- non-bilayer-forming lipids include lipids that are no more than weakly polar, preferably lipids that are substantially non- polar or neutral.
- the more-preferred lipids in the present invention are neutral lipids.
- the lipid particles used in the nanoemulsion of the present invention are distinguishable from the gas-containing microbubbles described in U.S. Patent Nos. 4684479 and 5215680, and are also structurally distinguishable from liposomes, such as those described, for example, in U.S. Patent Nos. 6565889 and 6596305, all herein incorporated by reference.
- the lipid particles are formed by a mixture of non-bilayer-forming lipids that are physiologically acceptable and at least substantially free from the presence of charged or polar lipids, including, for example, phospholipids.
- non- bilayer-forming lipids include those selected from glycerol monoesters of saturated and unsaturated carboxylic acids; glycerol monoesters of saturated aliphatic alcohols; sterol aromatic acid esters; sterols; terpenes; bile acids; alkali metal salts of bile acids; sterol esters of aliphatic acids; sterol esters of sugar acids; esters of sugar acids; esters of aliphatic alcohols; esters of sugars; esters of aliphatic acids; sugar acids; saponins; sapogenins; glycerol; glycerol di-esters of aliphatic acids; glycerol tri-esters of aliphatic acids; glycerol diesters of aliphatic alcohols; glycerol triesters of aliphatic alcohols; and combinations thereof.
- the lipid particles to be used to form the nanoemulsion are prepared by first forming a mixture of a select group of non-bilayer- forming lipids which provides the lipid particles with a size described hereinafter that facilitates high internalization levels when applied to targeted diseased tissues and cells.
- the lipid mixture generally comprises:
- At least one first member selected from the group consisting of glycerol monoesters of carboxylic acids containing from about 9 to 18 carbon atoms and aliphatic alcohols containing from about 10 to 18 carbon atoms;
- At least one third member selected from the group consisting of sterols, terpenes, bile acids and alkali metal salts of bile acids;
- lipid mixture described above only includes the presence of members (a) through (c), it is more preferred to incorporate members (d) and/or (e) because the long-term stability and uniformity of size of the lipid particles are theoretically enhanced by the presence of these two optional members.
- the five members (including the two optional members) making up the lipid mixture forming the lipid particles of the present invention are combined in a weight ratio of (a):(b):(c):(d):(e) of (l-5):(0.25-3):(0.25-3):(0- 3):(0-3), respectively.
- glycerol monoesters of saturated carboxylic acids containing from about 10 to 18 carbon atoms it is contemplated that glycerol monoesters of mono- or polyunsaturated carboxylic acids containing from about 9 to 18 carbon atoms, such as but not limited to the 9-carbon oleic or elaidic acids, are also useful in the construction of the lipid mixture.
- the proportions of the members of the lipid mixture may vary depending on several factors, including, but not limited to, the type of cells and/or tissues being targeted for delivery, the structure and desired dosage of any payload to be encapsulated within or otherwise associated with the nanoemulsion, the pharmaceutical ly- acceptable carrier used, the mode of administration, the presence of other excipients or additives, and so forth.
- factors that enable the lipid particles to be selectively internalized by targeted diseased tissues and cells include not only the composition of the lipid mixture and the structure of the resulting lipid particles but also the size and molecular weight of the particles as described hereinafter.
- the lipid particles of the present invention maintain a desirable particle size distribution, preferably where a major portion of the particles have a mean average particle size ranging from about 0.02 to 0.2 ⁇ , preferably 0.02 to 0.1 ⁇ , with varying minor amounts of particles falling above or below the range and some lipid particles only ranging up to about 200 ran.
- the particle size ranges attainable in the lipid particles of the present invention further lead to enhanced physical and chemical stability over an extended period of time, and substantial reduction in undesirable agglomeration and drug precipitation. Furthermore, this range is particularly suitable for the treatment of cancer; larger particles may be appropriate for other uses (e.g., targeting of other types of cells or tissues).
- the range provided herein will be determined in part by the lipid mixture employed and the type and amount of the imaging agent added.
- the imaging agent associated with the nanoemulsion of the present invention may be a fluorescent dye, such as, but not limited to, BODIPY, DiO, Eosin Y, and Erythrosine B.
- the imaging agent may be a labelled sterol, such as, but not limited to, BODIPY-cholesterol, NBD-cholesterol, and dansyl-cholesterol, and their associated cholesteryl esters.
- the imaging agent is radiolabelled, such as but not limited to l4 C-cholesterol,
- the imaging agent is radiolabelled, such as but not limited to l4 C-cholesterol
- the imaging agent associated with the nanoemulsion may itself be of therapeutic benefit upon delivery to the cell, based upon the properties of the imaging agent as well as the type of cell targeted. For example, should the imaging agent be Rose Bengal, therapeutic benefit would be expected to be demonstrated in a metastatic melanoma cell.
- the nanoemulsion of the present invention exhibits long-term physical and chemical stability, allowing such compositions to be conveniently pre-packaged into stable, ready-to- administer dosage forms and thereby eliminating the need for the bedside dilution and formulation prior to administration typically associated with similar compositions in the prior art.
- the nanoemulsion of the present invention exhibits desirable drug and emulsion stability over an extended time period (e.g., at least 14 days at about 30°C and at least 12 months at 4°C).
- the nanoemulsion of the present invention contains lipid particles in an amount of from about 0.1 ⁇ g/mL to 1000 ⁇ g/mL, preferably from about 10 ⁇ g/mL to 800 ⁇ g/mL, and most preferably from about 200 ⁇ g/mL to 600 ⁇ g/mL.
- Typical concentrations of the imaging agent based on the total volume of the nanoemulsion may be at least 0.001% w/v, preferably 0.001% to 90% w/v, and more preferably from about 0.1% to 25% w/v.
- the amount of imaging agent potentially present in the nanoemulsion may range from about 0.001 ⁇ . to 1000 ⁇ g/mL, preferably from about 0.1 ⁇ g/mL to 800 ⁇ .,, and more preferably from about 60 ⁇ g/mL to 400 ⁇ g/mL.
- the nanoemulsion of the present invention may further include emulsion-enhancing agents selected from a plant-based fat source, a solvent, a surfactant, or combinations thereof.
- emulsion-enhancing agents have been found, individually or in combination, to enhance the stability and maintain the small particle size properties of the lipid particles theoretically by reducing or minimizing undesirable precipitation or aggregation of the lipid particles, thereby positively influencing and facilitating the active uptake of the lipid particles into the cancer cells.
- the emulsion-enhancing agents should also improve the physical and chemical stability and drug-carrying capacity of the nanoemulsion of the present invention.
- the plant-based fat sources may be produced, derived, or modified from natural, chemical, or recombinant means.
- fat sources include vegetable-derived fatty acids generally in the form of vegetable oil, such as, for example, soybean oil, flaxseed oil, hemp oil, linseed oil, mustard oil, rapeseed oil, canola oil, safflower oil, sesame oil, sunflower oil, grape seed oil, almond oil, apricot oil, castor oil, corn oil, cottonseed oil, coconut oil, hazelnut oil, neem oil, olive oil, palm oil, palm kernel oil, peanut oil, pumpkin seed oil, rice bran oil, walnut oil, and mixtures thereof.
- the more preferred vegetable oil is soybean oil.
- the vegetable oil is generally present in amounts sufficient to permit higher surface tension in the nanoemulsion which in turn increases the probability of hydrophobic interactions with the plasma membranes of the target cell, or receptors thereupon.
- the plant- based fat source may be present in amounts of from about 0.001% v/v to 5.0% v/v, more preferably from about 0.005% v/v to 4.0% v/v, and most preferably from about 0.01% v/v to 2.5% v/v.
- the surfactants are those selected from non-ionic surfactants.
- non-ionic surfactants include sorbitan esters and mixtures thereof, such as fatty-acylated sorbitan esters and polyoxyethylene derivatives thereof, and mixtures thereof including, but not limited to, Poloxamer compounds (188, 182, 407 and 908), Tyloxapol, Polysorbate 20, 60 and 80, sodium glycolate, sodium dodecyl sulfate and the like, and combinations thereof.
- More preferred non-ionic surfactants are detergent polysorbates, such as, for example, Tween®-80.
- the surfactant is generally present in amounts sufficient to increase the kinetic stability of the nanoemulsion by stabilizing the interface between the hydrophobic and hydrophilic components of the nanoemulsion and keeping the hydrophobic components from coalescing, such that, once formed, the nanoemulsion does not significantly change in storage.
- the surfactant may be present in amounts of from about 0.01% w/v to 4.0% w/v, more preferably from about 0.1% w/v to 3.0% w/v, and most preferably from about 0.2% w/v to 2.5% w/v.
- the solvents include any pharmaceutically-acceptable water-miscible diluents or solvents such as, for example, polar protic and polar aprotic solvents.
- solvents are preferably selected from 1,3-butanediol; dimethyl sulfoxide; alcohols such as methanol, butanol, benzyl alcohol, isopropanol, and ethanol; and the like.
- a more preferred solvent is benzyl alcohol.
- the solvent is generally present in amounts sufficient to control the extent of the aggregation of non-ionic surfactants in the nanoemulsion.
- the solvent may be present in amounts of from about 0.001% v/v to 99.9% v/v, more preferably 0.005% v/v to 80% v/v, and most preferably from about 0.005% v/v to 70% v/v.
- composition of the present invention does not modify or alter the underlying pharmacological activity or chemical properties of the imaging agent but simply enhances its delivery to and internalization into the diseased cell or tissue, including cancerous cells or tissue, to impart imaging and/or therapeutic benefits.
- the nanoemulsion of the present invention is prepared by combining the lipid particles with the imaging agent and thoroughly mixing the same.
- the lipid mixture may be mixed with a surfactant in combination with a plant-based fat source prior to mixing with the imaging agent, which themselves may be mixed with a water-miscible solvent for dissolution.
- the lipid particle-imaging agent combination is then mixed with water, preferably purified water.
- the resulting mixture is then subjected to high shear forces typically produced in standard conventional shear-intensive homogenizing mixers or homogenizers to produce a nanoemulsion comprising the lipid particles dispersed within the aqueous phase.
- a suitable shear-intensive homogenizing mixer or homogenizer such as Microfluidizer® Fluid Materials Processors marketed by Microfluidics of Newton, MA.
- the resulting nanoemulsion may be further treated to yield a more purified form, which may be used for administration to warm-blooded animals, including humans.
- the nanoemulsion may be processed through dialysis to remove the impurities, with the resulting dialysate retained for pharmaceutical use. Dialysis is a preferred method of removing any non-particulated lipid mixture components, drugs, and/or solvents and achieving any desired buffer exchange or concentration.
- Dialysis membrane nominal molecular weight cutoffs of 5000 to 500000 can be used, with a molecular weight of 10000 to 300000 being preferred.
- the lipid particles produced as described, when purified such as by dialysis to remove non-particulated drug, may be characterized to determine the extent to which the lipid particles may be internalized in targeted cells, such as, for example, C 6 glioma cells.
- compositions of the present invention may further include a pharmaceutically- acceptable carrier or excipients.
- pharmaceutically-acceptable carriers are well known in the art and include those conventionally used in pharmaceutical compositions, such as, but not limited to, antioxidants, buffers, chelating agents, flavorants, colorants, preservatives, absorption promoters to enhance bioavailability, antimicrobial agents, and combinations thereof.
- the amount of such additives depends on the properties desired, which can readily be determined by one skilled in the art.
- the nanoemulsion of the present invention may routinely contain salts, buffering agents, preservatives, and compatible carriers, optionally in combination with other therapeutic ingredients.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically-acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically- and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, palicylic, p-toluene sulfonic, tartaric, citric, methane sulfonic, formic, malonic, succinic, naphthalene-2-sulfonic, and benzene sulfonic.
- pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
- the nanoemulsion of the present invention is useful in such cancer types as primary or metastatic melanoma, lymphoma, sarcoma, lung cancer, liver cancer, Hodgkin's and non-Hodgkin's lymphoma, leukemias, uterine cancer, cervical cancer, bladder cancer, kidney cancer, colon cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer.
- the nanoemulsion can be administered directly to a patient when combined with a pharmaceutically-acceptable carrier.
- This method may be practiced by administering the imaging agent alone or in combination with an effective amount of another therapeutic or diagnostic agent.
- This second agent may be, but is not limited to, a microtubule-interacting agent, a cytostatic agent, a folic acid inhibitor, an alkylating agent, a topoisomerase inhibitor, a tyrosine kinase inhibitor, a podophyllotoxin, an antitumor antibiotic, a chemotherapeutic agent, an apoptosis-inducing agent, and combinations thereof.
- Such therapeutic agents may further include metabolic inhibition reagents. Many such therapeutic agents are known in the art.
- the combination treatment method provides for simultaneous, sequential, or separate use in treating such conditions as needed to amplify or ensure patient response to the treatment method.
- compositions of the present invention may be practiced using any mode of administration that is medically acceptable, and produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
- formulations specifically suited for parenteral administration are preferred, the compositions of the present invention can also be formulated for inhalational, oral, topical, transdermal, nasal, ocular, pulmonary, rectal, transmucosal, intravenous, intramuscular, subcutaneous, intraperitoneal, intrathoracic, intrapleural, intrauterine, intratumoral, or infusion methodologies or administration, in the form of aerosols, sprays, powders, gels, lotions, creams, suppositories, ointments, and the like. If such a formulation is desired, other additives well-known in the art may be included to impart the desired consistency and other properties to the formulation.
- the particular mode of administering the imaging agent depends on the particular agent selected; whether the administration is for treatment, diagnosis, or imaging of a disease, condition, syndrome, or symptoms thereof; the severity of the medical disorder being imaged, treated or diagnosed; and the dosage required for efficacy.
- a preferred mode of administering an anticancer agent for treatment of leukemia would involve intravenous administration, whereas preferred methods for treating skin cancer could involve topical or intradermal administration.
- an effective amount refers to the dosage or multiple dosages of the imaging agent at which the desired imaging and/or therapeutic effect is achieved.
- an effective amount of the imaging agent may vary with the activity of the specific agent employed; the metabolic stability and length of action of that agent; the species, age, body weight, general health, dietary status, sex and diet of the subject; the mode and time of administration; rate of excretion; drug combination, if any; and extent of presentation and/or severity of the particular condition being treated.
- the dosage amount of the imaging agent used should be sufficient to inhibit or kill tumor cells while leaving normal cells substantially unharmed.
- the imaging agent included in the nanoemulsion of the present invention can be prepared in any amount desired up to the maximum amount that can be solubilized by, suspended in, or operatively associated with the given lipid particles.
- the amount of the imaging agent may range from 0.001 ⁇ g/mL to 1000 ⁇ g mL, preferably from about 0.1 ⁇ g/mL to 800 ⁇ g/mL, and more preferably about 300 ⁇ g/mL.
- the lipid particles will be delivered in a manner sufficient to administer an effective amount to the patient.
- the dosage amount may range from about 0.1 mg/kg to 175 mg/kg, preferably from about 1 mg/kg to 80 mg/kg, and more preferably 5 mg/kg to 60 mg/kg.
- the dosage amount may be administered in a single dose or in the form of individual divided doses, such as from one to four or more times per day. In the event that the response in a subject is insufficient at a certain dose, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent of patient tolerance. Multiple doses per day are contemplated to achieve appropriate systemic or targeted levels of the imaging agent.
- a method of preparing the nanoemulsion of the present invention comprising a lipid nanoemulsion comprising a dispersion of lipid particles wherein the dispersed phase of lipid particles are present in the form of macromolecules or clusters of small molecules on the nanoscale order of particle size.
- the lipid mixture and the imaging agent is combined with an aqueous phase comprising water, preferably filtered water.
- the resulting mixture is processed to form lipid particles having a mean average particle size range typically, but not always, in the range of up to 200 nm, a size particularly suited for the treatment of cancer, with larger particles appropriate for other uses.
- the range obtained will in part be affected by the lipid mixture employed, the type and amount of the imaging agent added to the lipid mixture, and the technique used to produce the lipid particles.
- the nanoemulsion of the present invention can be made using conventional dispersion-producing techniques or processes known in the art. Such techniques include, but are not limited to, high-shear homogenization, ultrasonic agitation or sonication, high- pressure homogenization, solvent emulsification/evaporation, and the like.
- the lipid particles may be prepared through conventional high-pressure homogenization techniques using a suitable high-pressure homogenizer. Homogenizers of suitable sizes are commercially available. High-pressure homogenizers are generally designed to push a fluid through a narrow gap spanning about a few microns at high pressure, typically from about 100 to 2000 bar.
- the pressurized fluid accelerates over a very short distance to a very high velocity of over 1000 km/hr.
- Pressurized fluids containing the lipid mixture encounter very high-shear stress and cavitation forces, effectively disrupting and comminuting the lipid mixture into particles in the submicron range.
- a major portion of the lipid particles should have a mean average particle size ranging from about 0.02 to 0.2 ⁇ , preferably 0.02 to 0.1 ⁇ , with varying minor amounts of particles falling above or below the range, especially with some lipid particles ranging up to about 200 nm.
- the lipid mixture may be mixed with a plant-based fat source, such as a vegetable oil, and a surfactant, such as a non- ionic surfactant, to yield a lipid phase.
- a surfactant such as a non- ionic surfactant
- the imaging agent may be mixed with a solvent, such as a water-miscible solvent, to yield an imaging phase.
- the lipid and imaging phases are thereafter mixed and blended together in the presence of an aqueous phase, preferably through sonication.
- the resulting mixture is thereafter homogenized under high-shear forces to produce the corresponding nanoemulsion of the present invention.
- the nanoemulsion may then be filtered through a 0.2 ⁇ membrane, sterilizing and/or removing impurities such as unused lipid materials, excess imaging agent, and so on, to yield a purified form suitable for delivery as a nanoemulsion to warm-blooded animals, including humans, in need of imaging and/or treatment.
- the objective of this investigation was to assess the uptake of the lipid-oil-water nanoemulsion of the present invention formulated with Eosin Y and Erythrosine in BXPC3 human pancreatic cancer cells and H460 non small lung carcinoma cells.
- BXPC3 human pancreatic cancer cells Two human tumor cell types, BXPC3 human pancreatic cancer cells and H460 non small lung carcinoma cells, were used in this investigation.
- the BXPC3 and H460 cells were originally obtained from American Type Cell Culture (ATCC). All tumor cells were maintained at 37°C in a humidified 5% C0 2 atmosphere in T75 tissue culture flasks containing 20mL of Roswell Park Memorial Institute (RPMI) 1640 containing 2mM L- glutamine, 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (lOOIU/mL penicillin and 100 ⁇ g/mL streptomycin). The tumor cells were split at a ratio of 1 :5 every 4-5 days by trypsinization and resuspended in fresh medium in a new flask. Cells were harvested for experiments at 70-90% confluency.
- ATCC American Type Cell Culture
- BXPC3 and H460 cells were seeded in a 96 well plate; 4x10 3 cells per well in ⁇ -, of RPMI medium containing 10% FBS. The cells were then incubated for approximately 24 hours before addition of nanoemulsion. The media was removed, and 50 ⁇ _- of Eosin Y and Erythrosine-containing nanoemulsion at a concentration of 300mg/L was added to the cells and incubated for 45 minutes. The nanoemulsion added to the cells were made by Dr. Frank Gibson of Cornerstone Pharmaceuticals, Inc., Cranbury, NJ.
- the cells were then washed three times in PBS, and the uptake of Eosin Y and Erythrosine-containing nanoemulsion was determined by measuring the fluorescence at excitation/emission wavelengths of 485/520 and 544/590nm using the FLUOstar OPTIMA plate reader.
- Eosin Y and Erythrosine-containing nanoemulsion was added to a 96-well plate, and the fluorescence was measured at excitation/emission wavelengths of 485/520 and 544/590nm. The average fluorescence was calculated by taking the mean of five replicates.
- Eosin Y The excitation/emission wavelengths of Eosin Y are 525/545nm and the excitation/emission wavelengths of Erythrosine are 530/558nm.
- Eosin Y-containing nanoemulsion showed higher uptake inside the cells at both wavelength ranges tested, compared to Erythrosine-containing nanoemulsion.
- the measurement of Eosin Y fluorescence in cancer cells at excitation/emission wavelengths of 485/520nm would provide a good system to study the uptake of the lipid-oil-water nanoemulsion of the present invention in cancer cells.
- the LN formulation used for these experiments was prepared as follows: non-polar lipids were solubilized in 95% ethanol to lOmg/mL by sonication for 10 minutes. ⁇ . of 0.5mg/mL cholesteryl BODIPY-FL (Molecular Probes, Eugene, OR) in ethanol was added to lmL of the lOmg/mL solubilized lipids.
- the lipid and cholesteryl BODIPY-FL mixture was added to 50mL of a solution of ImM sodium pyrophosphate in water and processed through a Microfluidics microfluidizer model 110Y (Microfluidics, Inc., Newton, MA).
- LN was prepared with 20( ⁇ g/mL lipids and 0.5% w/w cholesteryl-BODIPY-FL, by microfluidization.
- the cell lines chosen for analysis were HS-578T, MDA-MB-231, and MX-1 breast cancer, H23, H460, and H522 lung cancer, SF-539 glioblastoma, and HT29, SW-620, and COLO205 colon tumor cell lines. These cell lines were selected from those used by the National Cancer Institute (NCI)'s Developmental Therapeutics Program In Vitro Screening, which consists of cell lines representing different tumor types and derived from a number of different human tumor lineages.
- NCI National Cancer Institute
- Labelled LN was added to cells and incubated at 37°C, after which media was removed, the cells washed with PBS, trypsinized, washed again before fixation in 0.4% formaldehyde. Samples were analyzed by FACS and average fluorescence intensity per cell was determined. Average fluorescence intensity per cell for the colon, breast, central nervous system (CNS), and lung cell lines were compared to those of HT-29 colon carcinoma cell line and SF-539 glioblastoma cancer cell line, since these had been established through repeated experiments to take up low and high quantities of fluorescent LN, respectively. Fluorescent LN uptake by each LN-treated cell sample was obtained by subtracting the fluorescence intensity from the same cell line, which had been untreated.
- LN uptake varies among cell types of different lineages. Although some variability was seen among cells from the same tumor lineage, relative uptake was fairly consistent for each tumor lineage. For example, as is evident from FIGURES 3, 4, and 6, breast and lung tumor cell lines generally display higher LN uptake than did colon tumor cell lines. Overall, upon comparison, it is evident that the greatest LN uptake is observed in cell lines from liver and uterine tumors (Table 4), lung tumors (FIGURE 6), and CNS tumors (FIGURE 5).
- PAN 03 73.07 ⁇ 22.3 £ 4 ⁇ Average fluorescence intensity per cell was obtained for each fluorescent LN-treated sample, by comparing and subtracting fluorescence from the same respective untreated cell line.
- the present invention is directed to a delivery system in the form of a composition for delivering imaging and/or therapeutic agents, including anticancer agents, for treating cancerous cells and tissues. Accordingly, all anticancer agents are within the scope of the present invention, as well as all diseased tissues and cells exhibiting cellular hyperproliferation and aberrant lipid metabolism and elevated uptake of lipids, including cancer cells, which may be imaged and/or treated by such agents.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
Abstract
A stable lipid-oil-water nanoemulsion associated with an imaging agent is useful for imaging cells characterized by aberrant lipid metabolism and/or cellular hyperproliferation, such as cancer cells, in an exquisitely specific and selective manner compared to non-transformed cells.
Description
Imageable Lipid-Oil-Water Nanoemulsion Delivery System
Field of the Invention
This invention relates to therapeutic and diagnostic agents, and more particularly to a lipid-oil-water nanoemulsion suitable for introduction into a patient and capable of promoting both active selective agent concentration into cells characterized by aberrant lipid metabolism, including but not limited to tumor cells, and imaging and/or treatment of a primary or metastatic tumor formed by such cells. Background of the Invention
Response Criteria In Solid Tumors (RECIST), a set of unified anatomic imaging criteria for measuring tumor response to anticancer therapy based on a simplification of diverse but accepted international protocols, has been used in clinical oncology for nearly a decade. While voluntary, the use of RECIST is recommended for US National Cancer Institute-sponsored trials for the evaluation of experimental drugs in clinical trials from Phase II and beyond. Evaluation of response of the phase I clinical trials is rendered more difficult by an escalating dose, diverse patients with advanced disease and uncertainty as to imaging or other assay tools by which to measure response other than by survival. RECIST uses x- ray, computer aided tomography (CT), and magnetic resonance imaging (MRI) to extract linear measurements that are proposed to be an adequate substitute for two- or three- dimensional methods. Measurement and response is determined by comparative measurements of the most recent imaging results to measurements taken at time of diagnosis or at baseline prior to entering a clinical trial. Staging of disease may also taking into account alternative imaging techniques such as positron emission tomography (PET) using radiolabelled glucose, ultrasound, or imaging using radiolabelled antibodies which target
tumor specific antigens. A complete response is disappearance of all target lesions, while a partial response is a 30% decrease in the sum of the longest diameter of target lesions. Progressive disease is a 20% increase in the sum of the longest diameter of target lesions and/or the appearance of new tumors. Stable disease is considered to be small changes that do not meet the above criteria. To limit of detectability can affect interpretation of results as swelling of tumors can occur leading to an enlarged image even as tumor cells are responding to drug. Attempts to improve RECIST methodology include validating for clinical trial acceptable methods to incorporate volumetric three-dimensional anatomical imaging and the use of dynamic contrast imaging.
Historically, anatomical imaging has been fundamental to the evaluation of patients receiving drugs that are cytotoxic and expected to shrink tumors. It has been assumed not only that early determination of tumor shrinkage may potentially spare patients from experiencing those debilitating side effects accompanying chemotherapy but also that tumor shrinkage would correlate well with longer term survival. What has emerged in retrospective studies, however, is not only that tumor shrinkage may not always correlate well with longer term survival but also that metastatic disease as well as local relapse can contribute to disease-related death. Additionally, not all patients may respond to a drug at the same rate or in the same way. Furthermore, the emergence of new drugs with novel mechanisms of action has made the use of anatomical imaging questionable as an indicator for tumor response to drug. For example, where a drug has been found to be cytostatic, in some cases patients who would have been characterized under RECIST as having stable disease or a slowed trajectory of disease progression have gone on to achieve longer term survival than those patients receiving cytotoxic agents who would be considered responders under RECIST. In short, some drugs are able to help cancer be "managed" so that patients bearing tumors may nevertheless enjoy longer life expectancy and better life quality.
An additional confounding consideration for REC1ST is that with some targeted therapies, the drug-related mechanism of tumor cell death can influence what appears in an anatomical image and vary with time of treatment. For example, the dissolution and shrinkage of tumors is part of the final steps in a complicated cascade of cellular and sub- cellular local and immune system changes as a response to therapy. Under some circumstances, tumor swelling, edema, and inflammation can occur, phenomena which may suggest tumor enlargement or growth on an anatomical image. Such effects make the timing of taking the image, the kinetics of these effects, and the resolution of these effects critical. While the use of contrast agents and additional imaging methods may help better elucidate both what is occurring within the tumor and the kinetics thereof, in many situations an imaging center may lack the expertise, equipment, or resources to accurately reach the proper interpretation of the tumor image presented. Cancer specific necrosis, apoptosis, or autophagy, or a combination of these and the precise impact of the mechanism of cell death on the nature of an image obtained by the various imaging modalities is unknown. It has been suggested that mechanisms of cell death may be linked to the dying cell's metabolic state and location relative to tumor vasculature, as well as the influence of a variety of signal transduction ligands. Hence, a simple linear measurement of the longest tumor diameter is less likely to provide an adequate picture of intratumoral events. Using the current RECIST criteria, it is possible that patients who are in fact responding to a particular drug may show tumor enlargement on imaging by CT or related methods and thus be mistakenly withdrawn from study if imaged too early. Indeed, in a worst-case scenario, a patient could be denied a lifesaving therapeutic without real cause.
Collectively, these issues indicate an urgent need for a more accurate ability to understand the benefit of therapeutic or investigational therapeutic agents, or lack thereof, early in the course of treatment through the use of imaging. Knowing when to continue to
treat or to change a patient's therapeutic regimen is fundamental to optimizing cancer care. Any improved imaging technology should preferably use methodology and equipment that is or can be made widely available to generate results which can be standardized and validated as a predictor of longer term survival. Such an ability to accurately measure disease response to chemotherapy will most likely require an integration of imaging modalities and the use of biomarkers. Biomarkers related to a drug's mechanism of action may thus prove to be more valuable than disease-related markers, which may be highly variable among patients and stages of disease.
Medical imaging technologies have undergone explosive growth over the last few decades in the availability of methods and modalities as well as in the collection and interpretation of results. Imaging is consequently assuming an increasingly important role in both clinical trials and in the treatment of cancer patients. It has been stated in the art that molecular targeted imaging agents are expected to broadly expand the capabilities of conventional anatomical imaging methods, potentially allowing clinicians not only to see where tumors may be located but also to visualize the expression and activity of specific molecules (e.g. proteases or protein kinase) and biological processes (e.g., cancer metabolism, metastasis, angiogenesis, and apoptosis) that influence tumor behavior and/or response to therapy. (See Weissleder R (2006). Molecular imaging in cancer. Science 312: 1 168-71 , herein incorporated by reference.) It is anticipated that, upon validation through clinical studies, the use of molecular targeted imaging will be accepted as a biomarker, and perhaps ultimately as a surrogate endpoint, by the US FDA and worldwide regulatory agencies for clinical trials. This would result in smaller clinical trials requiring fewer patients, earlier go/no decisions for investigational drugs, a better understanding of dose-response relationships, faster regulatory approval for new drugs, and earlier use in clinical care in a manner that can be optimized for each patient.
The desired standard in the clinical practice of cancer imaging will thus most likely involve the use of targeted molecular imaging technology to accurately diagnose, manage, and treat many types of cancer. Targeted molecular imaging of cancer in combination with an anatomical imaging modality permits a physician to characterize a cancer mass' biological properties accurately and ultimately to select the treatment most likely to be effective based on the tumor's characteristics. Conventional imaging modalities, which often use additional contrast agents administered to the patient to enhance the quality of the images generated; these contrast agents often differ by the imaging modality used, and each contrast agent demonstrates different inherent strengths and limitations, such as toxicity. Additionally, through the use of molecular imaging technologies which exploit cancer's unique physiology, such as PET which uses small amounts of a variety of radioactive compounds to accurately and rapidly gauge the severity and spread of cancer by revealing the metabolic activity of cancer cells versus normal cells, a physician is now able to see within days of treatment through such cancer imaging how the tumor was affected by the therapy. Appropriate radiolabeled agents include 18-fluorodeoxyglucose (FDG) to measure metabolic activity of cancer cells versus normal cells, or radiolabeled nucleotides to measure cellular proliferation. A physician interpreting a PET image thereby gains visual and/or semi-quantitative information about treatment effectiveness much more quickly than through other conventional imaging modalities. Since responsive and nonresponsive disease can now theoretically be quickly differentiated, this is an important advance, as patients should not be detained from a potentially more effective treatment where one should be considered to exist. Further, patients experiencing a decreased quality of life as a result of being administered an ineffective drug should not have to endure a painful and disruptive side effect profile. Therefore earlier detected changes in cellular energy metabolism assessed by FDG PET are increasingly being relied upon to predict responses than are changes in tumor size. Indeed, it
has been reported for diverse indications that a significant decrease in cancer energy metabolism as detected by FDG PET correlates extremely well with longer term survival. Still, PET imaging has its shortfalls: the technique requires exposure to radiation, and some drugs may alter the ability for the radiolabelled agent to be taken up intracellularly without killing the tumor cells at a rate that is consistent with what appears on image. Additionally, false positives can occur on inflammation and invasion of tumors with infiltrating lymphocytes, or even on healing and fibrosis. Given these shortfalls, the ability to utilize molecular targeted ligands that are specific for cancer cells is therefore extremely important so as to enable distinguishing true disease response or progression from artifact.
As for other molecular targeted imaging approaches, measuring disruption of tumor blood flow and perfusion by MRI is another possible approach by which a physician may be able to see within days of treatment how tumors have been affected by the therapy. Finally, in the related field of radioimmunotherapy, molecularly-targeted isotopes can be delivered to specific targets within a cancer cell, concentrating cell-killing doses of radiation directly to a tumor mass, thereby decreasing radiation exposure to healthy tissue.
Distribution within tumors and their microenvironment of drugs and imaging agents is not been well understood. Higher doses of even the most potent drugs are often given to drive diffusion and encourage drug accumulation within a tumor mass. However, increasing drug concentration in a tumor mass does not always lead to increased intracellular drug concentration or the ability to reach an intracellular target organelle. Some drugs have been shown to increase concentration in a tumor mass by conjugation to polymers, liposome encapsulation, or solid lipid nanoparticle formulation. However, such conjugation or encapsulation may ultimately inhibit cellular uptake and consequently misdirect distribution. Higher dosing to drive tumor penetration by diffusion is also likely to increase the occurrence or intensity of side effects and contribute to the high morbidity of cancer treatment. It is
therefore desirable to devise a drug delivery technology that would improve drug penetration through tumor tissue and increase its concentration within tumor cells to the appropriate target organelle while simultaneously presenting an increased safety and efficacy profile. While diverse approaches have been explored for the passive accumulation of drugs into tumors, however, few technologies are available for the promotion of active tumor cell uptake. This is especially the case with targeted molecular imaging.
Lipid-soluble drugs readily penetrate cell membranes and may be transported through cells. Cells characterized by hyperproliferation, such as cancer cells, generally exhibit an aberrant lipid metabolism, marked by their greatly-increased preferential uptake of lipids and fatty acids. Indeed, it is not uncommon for cancer patients to present with low or depleted levels of serum lipids, including cholesterol. Upregulation of lipid receptors as well as changes in plasma membrane lipid raft compositions have been suggested to be associated with diverse solid tumor cell types and increased lipid uptake. Thus, with respect to cancer, lipids have been found to play essential roles in membrane structure, growth and metastasis, signal transduction, and transport processes.
Caused by the characteristic leaky features of tumor vasculature, the phenomenon known as the enhanced permeability and retention (EPR) effect for lipid particles, liposomes, synthetic nanoparticles, and other macromolecular agents is universal in solid tumors and has been explored for more selective targeting and tumor mass accumulation of, for example, polymer-conjugated anticancer drugs. The use of encapsulating agents such as polymeric vesicles, liposomes, and solid polymeric or lipid nanoparticles, each prepared in a variety of compositions, formulations, and structures and administered under a variety of physiological conditions, has been reported in the prior art. However, these agents permit only passive accumulation in tumors. Moreover, these agents are often rapidly cleared from the
circulation by extensive co-accumulation in the reticuloendothelial system, and often the use of these agents is associated with cytotoxicity and heightened immunoresponses.
Studies have shown that multiple receptor types and subtypes, transport proteins, and lipid raft phenomena are likely to be involved in lipid uptake into cancer cells, even among patients with the same disease but altered genetics. While lipid-based nanoparticles or HDL- or LDL-based drug carriers that mimic the natural receptor ligand and increase targeting and drug uptake into cancer cells have been prepared with various therapeutic agents, however, optimized formulations for the promotion of active tumor cell drug uptake, especially agents for the imaging of cancer, have been lacking.
Despite existing for almost a century, fluorescent dyes have relatively only recently been explored for their capability to act as targeted molecular imaging agents for cancer. While many classes of highly fluorescent organic compounds are known, over the past two decades dyes from the difluoro-boraindacene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) family (BODIPY) have been recognized as a photostable substitute for fluorescein. BODIPY's inherent photophysical properties, including excellent thermal and photochemical stability relative to fluorescein; high fluorescence quantum yield; negligible triplet-state formation and nanosecond excited-state lifetimes; intense absorption profile and large absorption coefficients; narrow emission profiles; good solubility; relative insensitivity to changes in polarity and pH; and large range of colors have all added to the general attractiveness of these fluorophore materials. Several new BODIPY-based dyes have thus been designed for and used as biological labelling reagents, with most current labelling studies involving the use of commercial materials bearing an anchor with which to attach the dye to the biological host.
3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) is a lipophilic carbocyanine green fluorescent dye which is weakly fluorescent in aqueous solutions but becomes highly
fluorescent and reasonably photostable when incorporated into cell membranes. DiO has been used as in neuronal and lymphocyte tracking studies and has recently been described as being useful as part of an organic, solvent-free, and specific method for the in vitro fluorescence confocal imaging of cancer cells using nanocrystals of DiO and perylene. (See Koichi Baba K, Kasai H, Masuhara A, Oikawa H, and Nakanishi H (2009). Organic solvent- free fluorescence confocal imaging of living cells using pure nanocrystal forms of fluorescent dyes. Jpn JAppl Phys 48: 1 17002, herein incorporated by reference.)
Eosin Y, an acidic fluorescent red dye, is a tetrabromo derivate of fluorescein used to stain basic parts of the cell, such as cytoplasm, collagen, red blood cells, and muscle fibers, for examination under the microscope. Eosin is most often used as a counterstain to Hematoxylin in H&E (Hematoxylin and Eosin) staining. For staining, Eosin Y is typically used in concentrations of 1 to 5 percent weight by volume, dissolved in water or ethanol; a small concentration (0.5 percent) of acetic acid usually gives a deeper red stain to the tissue.
Similarly, Erythrosine B, the disodium salt of 2,4,5,7-tetraiodofluorescein, is used as a cherry-pink biological stain and a radiopaque medium with a maximum absorbance at 530 nm in an aqueous solution. Because Erythrosine B is identical in structure to Eosin Y except that iodine is substituted for the bromines at each position on Eosin Y, Erythrosine B is often used as a substitute for Eosin Y staining.
Finally, the stain Rose Bengal (4,5,6,7-tetrachloro-2',4,,5,,7'-tetraiodofluorescein) is a nontoxic dye whose sodium salt is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby identify damage to the eye. This fluorescent stain has also been studied for its separate property as having a therapeutic effect on metastatic melanoma. In one study, 26 target lesions in eleven metastatic melanoma patients were directly injected with 10% w/v Rose Bengal in saline at a dose of 0.5 ml/cc lesion volume, with twenty-eight additional untreated lesions observed for potential bystander effect. The
treatment was well tolerated and an objective response was observed in twelve target lesions, with no cancer progression observed in seven lesions over at least three months of observation. Response rate was dose dependent, increasing to 69% after higher dose injections. Nontarget lesions exhibited a 27% objective response rate that increased to 44% in patients exhibiting a positive response of target lesions. It was concluded that intralesional Rose Bengal could benefit patients with metastatic melanoma. (See Thompson JF, Hersey P, and Wachter E (2008). Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18:405-11 , herein incorporated by reference.)
As an alternative to fluorescent stains or dyes, labelled cholesterol-derived sterols have been formulated in the past to be used to study the metabolism and intracellular localization of cholesterol, including a variety of photoreactive, spin-labelled, and fluorescent cholesterol analogues. (See, e.g., Gimpl G and Gehrig-Burger (2007). Cholesterol reporter molecules. Biosci. Rep. 27:335-358, herein incorporated by reference.) Although none of these analogues possess all of the properties of the parental cholesterol molecule, these molecules have been reported to localize in cholesterol-enriched microdomains. Photoreactive cholesterol probes such as cholesteryl diazoacetate; 3a-azido-5-cholestene; 3a- (4-azido-3-iodosalicylic)-cholest-5-ene; p-azidophenacyl 3a-hydroxy-5P-cholan-24-ate; 25- azidonorcholesterol; sterols with diazoacetate, aryldiazirines or fluorodiazirine attached at C- 22 or C-24; [3H]22-(p-benzoylphenoxy)-23,24-bisnorcholan-5-en-3p-ol; and [3H]6-azi-5a- cholestanol (i.e., photocholesterol) and [3H]7-azi-5a-cholestanol have been used to visualize the nicotinic acetylcholine receptor and oxytocin receptors and may be used to identify and analyze other putative cholesterol binding proteins at the molecular level. Spin-labelled cholesterol analogues having a nitroxide spin-label attached at the C-3 or C-25 position (e.g., 3 -doxyl-5a-cholestane) provide information about the structure of biological membranes, including the orientation, distribution and transbilayer movements of cholesterol in liposomes
and biological membranes, by using nuclear magnetic and electron spin resonance spectroscopy. Finally, to study the distribution and dynamics of cholesterol in membranes and cells, researchers can select among fluorescent cholesterol analogues, which are distinguished between those analogues which possess intrinsic fluorescence (e.g., dehydroergosterol and cholestatrienol) and those in which a fluorophore or photoreactive group is attached (e.g., NBD-cholesterol, BODIPY-cholesterol, and dansyl-cholestanol).
Such technology has also been used to analyze the potential efficacy of cholesterol- utilizing agents in the treatment of cancer. Thus, in light of the fact that receptors for vasoactive intestinal peptide (VIP) are overexpressed in human breast cancer, but that sterically stabilized liposomes (SSL) with VIP non-covalently associated on their surface were unable to actively target to breast cancer in rats in situ, most probably due to dissociation of non-covalently associated VIP from SSL, researchers covalently inserted VIP into BODIPY-cholesterol-labelled SSL and then incubated rat breast cancer tissue sections in vitro with the liposomes . The labelling technique verified that significantly more VIP-SSL were attached to rat breast cancer tissues, thereby indicating that SSL with covalently attached VIP can be actively targeted to rat breast cancer tissues. (See Dagar S, Sekosan M, Lee BS, I. Rubinstein I, and Onyuksel H (2001). VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J. Control. Release 74:129-134, herein incorporated by reference.)
Furthermore, to determine the transport of imaging probes attached to cholesterol and introduced via a liposomal formulation in order to evaluate the intracellular distribution and kinetics of small molecular cargo that might be attached to cholesterol or phospholipids, researchers compared BODIPY-cholesteryl ester and NBD-cholesterol to NBD- phosphatidylcholine and NBD-phosphatidylethanolamine using a liposomal formulation. It was discovered that the rate and transfer efficiency were NBD-cholesterol > BODIPY-
cholesteryl ester > NBD- phosphatidylcholine > NBD- phosphatidylethanolamine. While in the absence of polyethylene glycol (PEG) within the liposome, the transfer rate decreased, NBD-cholesterol, delivered by liposomes with an average diameter of 100 nm, localized in the perinuclear region and lipid storage droplets in a mostly time-constant manner with transfer observed in as little as five minutes, suggesting a unidirectional mode of entry. (See Kheirolomoom A and Ferrara KW (2007). Cholesterol transport from liposomal delivery vehicles. Biomaterials 28:4311-4120, herein incorporated by reference.) This study thus further highlights the desirability of utilizing labelled sterols to determine the efficacy of an appropriate drug delivery platform.
US Patents 4684479 and 5215680 to D'Arrigo, herein incorporated by reference, describe the formation of gas- or air-filled lipid coated microbubbles (LCMs), and methods of production and use thereof, to be used as imaging agents for ultrasound methods and for drug delivery. The production process for LCMs is based on simple mechanical shaking of an aqueous suspension of nonionic lipids, such as saturated glycerides and cholesterol esters, of specific chain lengths and in a fixed ratio. In all cases, the majority of lipids added (99%) flocculate or precipitate with additional loss of material on filtration with yields less than 1%. Still, these artificial LCMs were found to be very long-lived, lasting over 6 months in vitro. Also, despite their low filtration yields, LCMs are sufficiently small and pliable enough to pass across the fenestrated capillary walls of tumor-tissue microcirculation. Of particular note is the highly-selective, temperature-dependent, apparently saturable uptake of LCMs into rodent brain tumor cells as well as into spontaneous tumors in dogs, likely mimicking cancerous cells' natural uptake of certain lipids. To date, however, there has not been an efficacious formulation of a targeted molecular imaging agent utilizing LCM technology which presents minimal to nonexistent levels of adverse side effects upon patient administration.
Additionally, production methods are complex and small changes in conditions can result in significant differences in particle size and performance features. Typical approaches include high-shear homogenization and ultrasound, high-pressure homogenization, hot homogenization, cold homogenization, and solvent emulsification evaporation. Sterilization by aseptic filtration or radiation may also be complex. Thus, attempts to increase drug payload and solubility of lipids in LCMs with addition of a drug in ethanol and aqueous solution followed by high-shear homogenization result in the formation of poorly-stable non- gas-containing particles that contain little if any drug.
Lipid-oil-water nanoemulsions have also been described and prepared in the art. (See, e.g. , US Patent 7387790 to Shorr et al. ; Constantinides PP, Chaubal MV, and Shorr R (2008). Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev 60:757-67; and Barbarese E, Ho SY, D'Arrigo JS, and Simon RH (1995). Internalization of microbubbles by tumor cells in vivo and in vitro. J Neurooncol 26:25-34, all incorporated by reference.) Stability was achieved by modification of conditions of high shear homogenization. To date, however, there has not been an efficacious formulation of a targeted molecular imaging agent using lipid-oil-water nanoemulsion technology which presents minimal to nonexistent levels of adverse side effects upon patient administration.
Administering imaging agents with an appropriate delivery vehicle that simultaneously promotes accumulation and cellular internalization in a cancer mass but limits accumulation in healthy tissues to promote accurate imaging of the cancer mass is highly desirable. With more efficient delivery, systemic and healthy tissue concentrations of imaging agents may be reduced while achieving the same or better imaging results with fewer or diminished side effects. Further, a delivery vehicle that would not be limited to a single type of cancer but would allow for selective accumulation into a cancer mass and cellular internalization into diverse cancer cell types would be especially desirable and allow for safer
more effective treatment of cancer. A delivery vehicle that would also allow for elevated loading capacity for the imaging agent would be a significant advance in the art.
Overall, then, a major challenge in the treatment of cancer patients is the validation of biomarkers that can be utilized both to monitor benefits of drug treatment as well as to predict which patients would be most likely to benefit from any given drug or cocktail therapy. The ability to measure this increased uptake with a lipid-oil-water nanoemulsion that may also be used to deliver drug presents an opportunity to directly link a biomarker phenomenon to predicting the likelihood of therapeutic benefit. There is therefore a clear need for a stable, easily-prepared, biocompatible, efficacious formulation of targeted molecular imaging agents which would promote selective uptake into cancer cells to permit more accurate and more efficacious imaging of cancer.
Objects of the Invention and Industrial Applicability
Consequently, it is an object of the present invention to provide a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which exhibits rapid and increased selective and preferential uptake into tumor cells.
It is a further object of the present invention to provide a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which causes minimal side effects upon administration.
It is a still further object of the present invention to provide a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which is easily manufactured at the least possible cost and is capable of being stored for the longest possible period.
It is a still further object of the present invention to provide a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which permits a physician to select a more efficacious treatment modality for a cancer patient.
It is a still further object of the present invention to provide a targeted molecular imaging agent to be used for the imaging of diseases, conditions, and syndromes characterized by aberrant lipid metabolism, such as cancer, which may also impart therapeutic benefit.
Summary of the Invention
To achieve these objects, the present invention broadly provides a stable lipid-oil- water nanoemulsion that demonstrates dramatically increased and selective uptake and concentration into the cytosol of diseased, injured, or mutated cells of warm-blooded animals, including humans, compared to healthy cells. In a preferred embodiment of the present invention, the disease, injury, or mutation is characterized by aberrant lipid metabolism, and in a more preferred embodiment of the present invention, the disease is cancer. The lipid-oil- water nanoemulsion is comprised of lipid particles as hereinafter defined, uniformly dispersed through homogenization in an aqueous phase capable of being selectively and preferentially internalized within a diseased cell, including a cancer cell; an effective amount of at least one pharmaceutically-acceptable imaging agent associated with the lipid nanoemulsion; and a pharmaceutically-acceptable carrier or excipient therefor. The lipid particles each comprise at least one non-bilayer-forming lipid, among which the imaging agent is physically or chemically integrated. Such suitable lipid particles have been found to enhance significantly the targeted delivery and concentration of an associated payload into diseased cells characterized by aberrant lipid metabolism, including cancer cells. Moreover,
the nanoemulsion exhibits exceptional physical and chemical stability for an extended duration of time, thereby greatly facilitating prepackaging of the nanoemulsion in stable, ready-to-administer forms.
In one embodiment of the present invention, the imaging agent may be a fluorescent dye, such as, but not limited to, BODIPY, DiO, Rose Bengal, Eosin Y, and Erythrosine B. In another embodiment of the present invention, the imaging agent may be a labelled sterol, such as, but not limited to, BODIPY-cholesterol, NBD-cholesterol, and dansyl-cholesterol, and their associated cholesteryl esters. In yet another embodiment of the present invention, the imaging agent is radiolabelled, such as, but not limited to, 14C-cholesterol. Upon administration of the nanoemulsion either to a patient in vivo or obtained from patient biopsy in vitro, the demonstration of increased uptake into cancer cells associated with a particular tumor type upon use of an imaging modality such as x-ray, CT, PET, or MRI, without limitation, or lack thereof, is expected to be a useful indicator of the potential benefits to be achieved by delivering a chemotherapeutic agent known to be efficacious in treating that tumor type. Furthermore, any component of the nanoemulsion of the present invention (e.g., the lipid particles or the labelled moiety) may act as an antigen, or conversely as an antibody, which may be detected through immunologic-based imaging modalities, such as immunofluorescence.
In a still further aspect of the present invention, there is provided a method of preparing the nanoemulsion disclosed herein, comprising the steps of:
a) mixing the at least one non-bilayer-forming lipid with an effective amount of at least one imaging agent to yield a lipid portion;
b) adding the lipid portion to an aqueous phase to yield a dispersion; and
c) agitating the dispersion under high-shear conditions sufficient to disperse the aforementioned lipid therethrough to form a lipid nanoemulsion comprised of lipid particles.
Brief Description of the Drawings
The following drawings are illustrative of embodiments of the invention and are not intended to limit the scope of the application as encompassed by the entire specification and claims.
FIGURE 1 illustrates data demonstrating that the uptake of the lipid nanoparticles of the present invention is directly proportional to their concentration.
FIGURE 2 shows data demonstrating that the uptake of the lipid nanoparticles of the present invention is a function of time.
FIGURE 3 depicts data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in colon tumor-derived cell lines.
FIGURE 4 portrays data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in breast tumor-derived cell lines.
FIGURE 5 illustrates data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in central nervous system tumor-derived cell lines.
FIGURE 6 depicts data demonstrating the relative uptake of the lipid-oil-water nanoemulsion of the present invention in lung tumor-derived cell lines.
FIGURE 7 illustrates the results of an experiment to determine to the amount of uptake of the lipid-oil-water nanoemulsion of the present invention where one component of the nanoemulsion is systematically deleted from the final composition.
FIGURE 8 shows the results of an experiment to determine to the amount of uptake of the lipid-oil-water nanoemulsion of the present invention where one component of the nanoemulsion is mixed 1 : 1 with cholesterol to form the lipid nanoparticles administered to the cells.
Detailed Description of the Invention
The present invention is generally directed to a stable lipid-oil-water nanoemulsion that demonstrates dramatically increased and selective uptake and concentration into the cytosol of diseased, injured, or mutated cells in warm-blooded animals compared to healthy cells. Such warm-blooded animals include those of the mammalian class, such as humans, horses, cattle, domestic animals including dogs and cats, and the like, subject to disease, injury, mutation, and other pathological conditions and syndromes. In a preferred embodiment of the present invention, the disease, injury, or mutation is characterized by aberrant lipid metabolism, and in a more preferred embodiment of the present invention, the disease is cancer. The nanoemulsion is comprised of lipid particles as hereinafter defined, uniformly dispersed through homogenization in an aqueous phase capable of being selectively and preferentially internalized within a cell characterized by aberrant lipid metabolism, including a cancer cell; an effective amount of at least one pharmaceutically- acceptable imaging agent associated with the lipid nanoemulsion; and a pharmaceutically- acceptable carrier or excipient therefor, thereby making the lipid particles particularly well- suited for the selective delivery to and effective concentration within such diseased cells and tissues as tumorous ones.
The lipid particles of the nanoemulsion are structured to facilitate both elevated passive accumulation and active internalization into diseased cells and tissues, including tumor cells and tissues. The lipid particles are taken into these cells through active metabolic uptake as they passively accumulate in the vascular area of the diseased tissue. Thus, the lipid particles of the present invention provide a delivery vehicle selectively and preferentially targeted for uptake and internalization by cells characterized by aberrant lipid metabolism, including tumor and cancer cells. "Internalization" as used herein means that the lipid particles are actively taken up by the cell.
The lipid particles of the nanoemulsion are exceptionally physically and chemically stable over an extended period of time and hence experience minimal loss of imaging or therapeutic capability due to undesirable precipitation, aggregation, or insolubility that is typically exhibited in delivery systems in the prior art. Moreover, these lipid particles display other favorable characteristics including controlled release; enhanced drug stability; positive drug loading capacity; better compatibility with hydrophobic drugs; relatively low biotoxicity; and low organic solvent content. The lipid particles are also relatively simple and convenient to prepare and to administer.
As used herein, the term "lipid particle" is meant to encompass any lipid-containing structures, typically nanosized, which are at least substantially-intact particles forming part of a nanoemulsion. The term "substantially-intact" means that the particles maintain their shape in the absence of a membrane, as contrasted with a liposome. The lipid particles are comprised of at least one non-bilayer-forming lipid.
A lipid bilayer structure or arrangement is typically formed by certain kinds of lipids having a hydrophilic end (polar head region) and a hydrophobic end (nonpolar tail region), including amphipathic molecules such as phospholipids, which exhibit the ability and/or tendency to self-organize into two opposing layers of lipid molecules in aqueous solution. The two opposing layers of lipid molecules are arranged so that their hydrophobic ends face one another to form an oily core, while their hydrophilic ends face the aqueous solutions on either side of the bilayer structure. In the present invention, the term "non-bilayer-forming lipid" encompasses a lipid that lacks such ability and/or tendency to form a lipid bilayer structure or arrangement in an aqueous environment. Examples of non-bilayer-forming lipids include lipids that are no more than weakly polar, preferably lipids that are substantially non- polar or neutral. The more-preferred lipids in the present invention are neutral lipids.
The lipid particles used in the nanoemulsion of the present invention are
distinguishable from the gas-containing microbubbles described in U.S. Patent Nos. 4684479 and 5215680, and are also structurally distinguishable from liposomes, such as those described, for example, in U.S. Patent Nos. 6565889 and 6596305, all herein incorporated by reference. In particular, the lipid particles are formed by a mixture of non-bilayer-forming lipids that are physiologically acceptable and at least substantially free from the presence of charged or polar lipids, including, for example, phospholipids. Suitable examples of non- bilayer-forming lipids include those selected from glycerol monoesters of saturated and unsaturated carboxylic acids; glycerol monoesters of saturated aliphatic alcohols; sterol aromatic acid esters; sterols; terpenes; bile acids; alkali metal salts of bile acids; sterol esters of aliphatic acids; sterol esters of sugar acids; esters of sugar acids; esters of aliphatic alcohols; esters of sugars; esters of aliphatic acids; sugar acids; saponins; sapogenins; glycerol; glycerol di-esters of aliphatic acids; glycerol tri-esters of aliphatic acids; glycerol diesters of aliphatic alcohols; glycerol triesters of aliphatic alcohols; and combinations thereof.
In an embodiment of the present invention, the lipid particles to be used to form the nanoemulsion are prepared by first forming a mixture of a select group of non-bilayer- forming lipids which provides the lipid particles with a size described hereinafter that facilitates high internalization levels when applied to targeted diseased tissues and cells. The lipid mixture generally comprises:
a) at least one first member selected from the group consisting of glycerol monoesters of carboxylic acids containing from about 9 to 18 carbon atoms and aliphatic alcohols containing from about 10 to 18 carbon atoms;
b) at least one second member selected from the group consisting of sterol aromatic acid esters;
c) at least one third member selected from the group consisting of sterols, terpenes,
bile acids and alkali metal salts of bile acids;
d) at least one optional fourth member selected from the group consisting of sterol esters of aliphatic acids containing from about 1 to 18 carbon atoms; sterol esters of sugar acids; esters of sugar acids and aliphatic alcohols containing from about 10 to 18 carbon atoms, esters of sugars and aliphatic acids containing from about 10 to 18 carbon atoms; sugar acids, saponins; and sapogenins; and
e) at least one optional fifth member selected from the group consisting of glycerol, glycerol di- or tri-esters of aliphatic acids containing from about 10 to 18 carbon atoms and aliphatic alcohols containing from about 10 to 18 carbon atoms.
While the lipid mixture described above only includes the presence of members (a) through (c), it is more preferred to incorporate members (d) and/or (e) because the long-term stability and uniformity of size of the lipid particles are theoretically enhanced by the presence of these two optional members.
In a preferred embodiment of the present invention, the five members (including the two optional members) making up the lipid mixture forming the lipid particles of the present invention are combined in a weight ratio of (a):(b):(c):(d):(e) of (l-5):(0.25-3):(0.25-3):(0- 3):(0-3), respectively.
While the first member of the lipid mixture has been described as including glycerol monoesters of saturated carboxylic acids containing from about 10 to 18 carbon atoms, it is contemplated that glycerol monoesters of mono- or polyunsaturated carboxylic acids containing from about 9 to 18 carbon atoms, such as but not limited to the 9-carbon oleic or elaidic acids, are also useful in the construction of the lipid mixture.
It will be understood that the proportions of the members of the lipid mixture may vary depending on several factors, including, but not limited to, the type of cells and/or tissues being targeted for delivery, the structure and desired dosage of any payload to be
encapsulated within or otherwise associated with the nanoemulsion, the pharmaceutical ly- acceptable carrier used, the mode of administration, the presence of other excipients or additives, and so forth. Furthermore, factors that enable the lipid particles to be selectively internalized by targeted diseased tissues and cells include not only the composition of the lipid mixture and the structure of the resulting lipid particles but also the size and molecular weight of the particles as described hereinafter.
The lipid particles of the present invention maintain a desirable particle size distribution, preferably where a major portion of the particles have a mean average particle size ranging from about 0.02 to 0.2 μιη, preferably 0.02 to 0.1 μπι, with varying minor amounts of particles falling above or below the range and some lipid particles only ranging up to about 200 ran. The particle size ranges attainable in the lipid particles of the present invention further lead to enhanced physical and chemical stability over an extended period of time, and substantial reduction in undesirable agglomeration and drug precipitation. Furthermore, this range is particularly suitable for the treatment of cancer; larger particles may be appropriate for other uses (e.g., targeting of other types of cells or tissues). The range provided herein will be determined in part by the lipid mixture employed and the type and amount of the imaging agent added.
In one embodiment of the present invention, the imaging agent associated with the nanoemulsion of the present invention may be a fluorescent dye, such as, but not limited to, BODIPY, DiO, Eosin Y, and Erythrosine B. In another embodiment of the present invention, the imaging agent may be a labelled sterol, such as, but not limited to, BODIPY-cholesterol, NBD-cholesterol, and dansyl-cholesterol, and their associated cholesteryl esters. In yet another embodiment of the present invention, the imaging agent is radiolabelled, such as but not limited to l4C-cholesterol, Upon administration of the nanoemulsion either to a patient in vivo or obtained from patient biopsy in vitro, the demonstration of increased uptake into
cancer cells associated with a particular tumor type upon use of an imaging modality such as x-ray, CT, PET, or MRI, without limitation, or lack thereof, is expected to be a useful indicator of the potential benefits to be achieved by delivering a chemotherapeutic agent known to be efficacious in treating that tumor type.
The imaging agent associated with the nanoemulsion may itself be of therapeutic benefit upon delivery to the cell, based upon the properties of the imaging agent as well as the type of cell targeted. For example, should the imaging agent be Rose Bengal, therapeutic benefit would be expected to be demonstrated in a metastatic melanoma cell.
The nanoemulsion of the present invention exhibits long-term physical and chemical stability, allowing such compositions to be conveniently pre-packaged into stable, ready-to- administer dosage forms and thereby eliminating the need for the bedside dilution and formulation prior to administration typically associated with similar compositions in the prior art. The nanoemulsion of the present invention exhibits desirable drug and emulsion stability over an extended time period (e.g., at least 14 days at about 30°C and at least 12 months at 4°C). The nanoemulsion of the present invention contains lipid particles in an amount of from about 0.1 μg/mL to 1000 μg/mL, preferably from about 10 μg/mL to 800 μg/mL, and most preferably from about 200 μg/mL to 600 μg/mL. Typical concentrations of the imaging agent based on the total volume of the nanoemulsion may be at least 0.001% w/v, preferably 0.001% to 90% w/v, and more preferably from about 0.1% to 25% w/v. The amount of imaging agent potentially present in the nanoemulsion may range from about 0.001 μ^πιΐ. to 1000 μg/mL, preferably from about 0.1 μg/mL to 800 μ^πιΐ.,, and more preferably from about 60 μg/mL to 400 μg/mL.
The nanoemulsion of the present invention may further include emulsion-enhancing agents selected from a plant-based fat source, a solvent, a surfactant, or combinations thereof. The emulsion-enhancing agents have been found, individually or in combination, to enhance
the stability and maintain the small particle size properties of the lipid particles theoretically by reducing or minimizing undesirable precipitation or aggregation of the lipid particles, thereby positively influencing and facilitating the active uptake of the lipid particles into the cancer cells. The emulsion-enhancing agents should also improve the physical and chemical stability and drug-carrying capacity of the nanoemulsion of the present invention.
In a preferred embodiment of the present invention, the plant-based fat sources may be produced, derived, or modified from natural, chemical, or recombinant means. Examples of such fat sources include vegetable-derived fatty acids generally in the form of vegetable oil, such as, for example, soybean oil, flaxseed oil, hemp oil, linseed oil, mustard oil, rapeseed oil, canola oil, safflower oil, sesame oil, sunflower oil, grape seed oil, almond oil, apricot oil, castor oil, corn oil, cottonseed oil, coconut oil, hazelnut oil, neem oil, olive oil, palm oil, palm kernel oil, peanut oil, pumpkin seed oil, rice bran oil, walnut oil, and mixtures thereof. The more preferred vegetable oil is soybean oil.
The vegetable oil is generally present in amounts sufficient to permit higher surface tension in the nanoemulsion which in turn increases the probability of hydrophobic interactions with the plasma membranes of the target cell, or receptors thereupon. The plant- based fat source may be present in amounts of from about 0.001% v/v to 5.0% v/v, more preferably from about 0.005% v/v to 4.0% v/v, and most preferably from about 0.01% v/v to 2.5% v/v.
In another preferred embodiment of the present invention, the surfactants are those selected from non-ionic surfactants. Examples of non-ionic surfactants include sorbitan esters and mixtures thereof, such as fatty-acylated sorbitan esters and polyoxyethylene derivatives thereof, and mixtures thereof including, but not limited to, Poloxamer compounds (188, 182, 407 and 908), Tyloxapol, Polysorbate 20, 60 and 80, sodium glycolate, sodium dodecyl sulfate and the like, and combinations thereof. More preferred non-ionic surfactants
are detergent polysorbates, such as, for example, Tween®-80.
The surfactant is generally present in amounts sufficient to increase the kinetic stability of the nanoemulsion by stabilizing the interface between the hydrophobic and hydrophilic components of the nanoemulsion and keeping the hydrophobic components from coalescing, such that, once formed, the nanoemulsion does not significantly change in storage. The surfactant may be present in amounts of from about 0.01% w/v to 4.0% w/v, more preferably from about 0.1% w/v to 3.0% w/v, and most preferably from about 0.2% w/v to 2.5% w/v.
In yet another preferred embodiment of the present invention, the solvents include any pharmaceutically-acceptable water-miscible diluents or solvents such as, for example, polar protic and polar aprotic solvents. Such solvents are preferably selected from 1,3-butanediol; dimethyl sulfoxide; alcohols such as methanol, butanol, benzyl alcohol, isopropanol, and ethanol; and the like. A more preferred solvent is benzyl alcohol.
The solvent is generally present in amounts sufficient to control the extent of the aggregation of non-ionic surfactants in the nanoemulsion. The solvent may be present in amounts of from about 0.001% v/v to 99.9% v/v, more preferably 0.005% v/v to 80% v/v, and most preferably from about 0.005% v/v to 70% v/v.
The composition of the present invention does not modify or alter the underlying pharmacological activity or chemical properties of the imaging agent but simply enhances its delivery to and internalization into the diseased cell or tissue, including cancerous cells or tissue, to impart imaging and/or therapeutic benefits.
Generally, the nanoemulsion of the present invention is prepared by combining the lipid particles with the imaging agent and thoroughly mixing the same. The lipid mixture may be mixed with a surfactant in combination with a plant-based fat source prior to mixing with the imaging agent, which themselves may be mixed with a water-miscible solvent for
dissolution. The lipid particle-imaging agent combination is then mixed with water, preferably purified water. The resulting mixture is then subjected to high shear forces typically produced in standard conventional shear-intensive homogenizing mixers or homogenizers to produce a nanoemulsion comprising the lipid particles dispersed within the aqueous phase. Sufficient high shear forces can be produced with a suitable shear-intensive homogenizing mixer or homogenizer such as Microfluidizer® Fluid Materials Processors marketed by Microfluidics of Newton, MA. The resulting nanoemulsion may be further treated to yield a more purified form, which may be used for administration to warm-blooded animals, including humans.
In some instances, it may be desirable to remove unduly large particles from the mixing process, so as to maintain the particle size distribution within a desired range. Suitable filtration systems, such as those from Millipore Corporation of Waltham, Massachusetts, are available for this purpose. The selection of a suitable filter system therefore may be a factor in controlling the particle size distribution of the lipid particles within a desirable range and is within the routine skill of the skilled artisan. Alternatively, the nanoemulsion may be processed through dialysis to remove the impurities, with the resulting dialysate retained for pharmaceutical use. Dialysis is a preferred method of removing any non-particulated lipid mixture components, drugs, and/or solvents and achieving any desired buffer exchange or concentration. Dialysis membrane nominal molecular weight cutoffs of 5000 to 500000 can be used, with a molecular weight of 10000 to 300000 being preferred. The lipid particles produced as described, when purified such as by dialysis to remove non-particulated drug, may be characterized to determine the extent to which the lipid particles may be internalized in targeted cells, such as, for example, C6 glioma cells.
The compositions of the present invention may further include a pharmaceutically-
acceptable carrier or excipients. Examples of pharmaceutically-acceptable carriers are well known in the art and include those conventionally used in pharmaceutical compositions, such as, but not limited to, antioxidants, buffers, chelating agents, flavorants, colorants, preservatives, absorption promoters to enhance bioavailability, antimicrobial agents, and combinations thereof. The amount of such additives depends on the properties desired, which can readily be determined by one skilled in the art.
The nanoemulsion of the present invention may routinely contain salts, buffering agents, preservatives, and compatible carriers, optionally in combination with other therapeutic ingredients. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically-acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically- and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, palicylic, p-toluene sulfonic, tartaric, citric, methane sulfonic, formic, malonic, succinic, naphthalene-2-sulfonic, and benzene sulfonic. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
Improved imaging of cancer through the use of the nanoemulsion of the present invention is especially contemplated, including imaging of primary tumors prior to or concurrent with surgical removal, or radiological or other chemotherapeutic treatment of a primary tumor. The nanoemulsion of the present invention is useful in such cancer types as primary or metastatic melanoma, lymphoma, sarcoma, lung cancer, liver cancer, Hodgkin's and non-Hodgkin's lymphoma, leukemias, uterine cancer, cervical cancer, bladder cancer, kidney cancer, colon cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer.
For imaging and therapeutic applications, the nanoemulsion can be administered directly to a patient when combined with a pharmaceutically-acceptable carrier. This method may be practiced by administering the imaging agent alone or in combination with an effective amount of another therapeutic or diagnostic agent. This second agent may be, but is not limited to, a microtubule-interacting agent, a cytostatic agent, a folic acid inhibitor, an alkylating agent, a topoisomerase inhibitor, a tyrosine kinase inhibitor, a podophyllotoxin, an antitumor antibiotic, a chemotherapeutic agent, an apoptosis-inducing agent, and combinations thereof. Such therapeutic agents may further include metabolic inhibition reagents. Many such therapeutic agents are known in the art. The combination treatment method provides for simultaneous, sequential, or separate use in treating such conditions as needed to amplify or ensure patient response to the treatment method.
The methods of the present invention may be practiced using any mode of administration that is medically acceptable, and produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Although formulations specifically suited for parenteral administration are preferred, the compositions of the present invention can also be formulated for inhalational, oral, topical, transdermal, nasal, ocular, pulmonary, rectal, transmucosal, intravenous, intramuscular, subcutaneous, intraperitoneal, intrathoracic, intrapleural, intrauterine, intratumoral, or infusion methodologies or administration, in the form of aerosols, sprays, powders, gels, lotions, creams, suppositories, ointments, and the like. If such a formulation is desired, other additives well-known in the art may be included to impart the desired consistency and other properties to the formulation.
Those skilled in the art will recognize that the particular mode of administering the imaging agent depends on the particular agent selected; whether the administration is for treatment, diagnosis, or imaging of a disease, condition, syndrome, or symptoms thereof; the severity of the medical disorder being imaged, treated or diagnosed; and the dosage required
for efficacy. For example, a preferred mode of administering an anticancer agent for treatment of leukemia would involve intravenous administration, whereas preferred methods for treating skin cancer could involve topical or intradermal administration.
As used herein, "effective amount" refers to the dosage or multiple dosages of the imaging agent at which the desired imaging and/or therapeutic effect is achieved. Generally, an effective amount of the imaging agent may vary with the activity of the specific agent employed; the metabolic stability and length of action of that agent; the species, age, body weight, general health, dietary status, sex and diet of the subject; the mode and time of administration; rate of excretion; drug combination, if any; and extent of presentation and/or severity of the particular condition being treated. The precise dosage can be determined by an artisan of ordinary skill in the art without undue experimentation, in one or several administrations per day, to yield the desired results, and the dosage may be adjusted by the individual practitioner to achieve a desired imaging and/or therapeutic effect or in the event of any complication. Importantly, when used to treat cancer, the dosage amount of the imaging agent used should be sufficient to inhibit or kill tumor cells while leaving normal cells substantially unharmed.
The imaging agent included in the nanoemulsion of the present invention can be prepared in any amount desired up to the maximum amount that can be solubilized by, suspended in, or operatively associated with the given lipid particles. The amount of the imaging agent may range from 0.001 μg/mL to 1000 μg mL, preferably from about 0.1 μg/mL to 800 μg/mL, and more preferably about 300 μg/mL.
Generally, the lipid particles will be delivered in a manner sufficient to administer an effective amount to the patient. The dosage amount may range from about 0.1 mg/kg to 175 mg/kg, preferably from about 1 mg/kg to 80 mg/kg, and more preferably 5 mg/kg to 60 mg/kg. The dosage amount may be administered in a single dose or in the form of individual
divided doses, such as from one to four or more times per day. In the event that the response in a subject is insufficient at a certain dose, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent of patient tolerance. Multiple doses per day are contemplated to achieve appropriate systemic or targeted levels of the imaging agent.
In another aspect of the present invention, there is provided a method of preparing the nanoemulsion of the present invention. The lipid mixture is incorporated into the imaging agent in amounts such that, upon processing with an aqueous phase, the composition forms a lipid nanoemulsion comprising a dispersion of lipid particles wherein the dispersed phase of lipid particles are present in the form of macromolecules or clusters of small molecules on the nanoscale order of particle size. In preparing the nanoemulsion of the present invention, the lipid mixture and the imaging agent is combined with an aqueous phase comprising water, preferably filtered water. The resulting mixture is processed to form lipid particles having a mean average particle size range typically, but not always, in the range of up to 200 nm, a size particularly suited for the treatment of cancer, with larger particles appropriate for other uses. The range obtained will in part be affected by the lipid mixture employed, the type and amount of the imaging agent added to the lipid mixture, and the technique used to produce the lipid particles.
The nanoemulsion of the present invention can be made using conventional dispersion-producing techniques or processes known in the art. Such techniques include, but are not limited to, high-shear homogenization, ultrasonic agitation or sonication, high- pressure homogenization, solvent emulsification/evaporation, and the like. In one embodiment of the present invention, the lipid particles may be prepared through conventional high-pressure homogenization techniques using a suitable high-pressure homogenizer. Homogenizers of suitable sizes are commercially available. High-pressure
homogenizers are generally designed to push a fluid through a narrow gap spanning about a few microns at high pressure, typically from about 100 to 2000 bar. The pressurized fluid accelerates over a very short distance to a very high velocity of over 1000 km/hr. Pressurized fluids containing the lipid mixture encounter very high-shear stress and cavitation forces, effectively disrupting and comminuting the lipid mixture into particles in the submicron range. As previously discussed, a major portion of the lipid particles should have a mean average particle size ranging from about 0.02 to 0.2 μπι, preferably 0.02 to 0.1 μπι, with varying minor amounts of particles falling above or below the range, especially with some lipid particles ranging up to about 200 nm.
In another particular method of preparing the lipid particles, the lipid mixture may be mixed with a plant-based fat source, such as a vegetable oil, and a surfactant, such as a non- ionic surfactant, to yield a lipid phase. The imaging agent may be mixed with a solvent, such as a water-miscible solvent, to yield an imaging phase. The lipid and imaging phases are thereafter mixed and blended together in the presence of an aqueous phase, preferably through sonication. The resulting mixture is thereafter homogenized under high-shear forces to produce the corresponding nanoemulsion of the present invention. The nanoemulsion may then be filtered through a 0.2 μιη membrane, sterilizing and/or removing impurities such as unused lipid materials, excess imaging agent, and so on, to yield a purified form suitable for delivery as a nanoemulsion to warm-blooded animals, including humans, in need of imaging and/or treatment.
The following examples are provided to facilitate understanding of the nanoemulsion of the present invention.
EXAMPLE 1
MEASUREMENT OF EOSIN Y AND ERYTHROSINE FLUORESCENCE IN H460
AND BXPC3 CELLS
Objective
The objective of this investigation was to assess the uptake of the lipid-oil-water nanoemulsion of the present invention formulated with Eosin Y and Erythrosine in BXPC3 human pancreatic cancer cells and H460 non small lung carcinoma cells.
Materials and Methods
Materials
All materials were obtained through normal distribution channels from the manufacturer stated.
Costar® 96 well plate, Corning Costar Corporation, Cambridge, MA, cat. no. 3598 Fisher Scientific cat no.07-200-628 FLUOstar OPTIMA, BMG LABTECH, Offenburg, Germany
RPMI 1640 Tissue culture medium. Mediatech. Fisher Scientific cat. no. MT- 10040-
CV
Fetal Bovine Serum (FBS) Fisher Scientific cat. no. MTT35011CV
Penicillin and Steptomycin. Fisher Scientific cat. no. MT 30-009-CI
Tumor Cell Lines
Two human tumor cell types, BXPC3 human pancreatic cancer cells and H460 non small lung carcinoma cells, were used in this investigation. The BXPC3 and H460 cells were originally obtained from American Type Cell Culture (ATCC). All tumor cells were maintained at 37°C in a humidified 5% C02 atmosphere in T75 tissue culture flasks
containing 20mL of Roswell Park Memorial Institute (RPMI) 1640 containing 2mM L- glutamine, 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (lOOIU/mL penicillin and 100μg/mL streptomycin). The tumor cells were split at a ratio of 1 :5 every 4-5 days by trypsinization and resuspended in fresh medium in a new flask. Cells were harvested for experiments at 70-90% confluency.
Measurement of Eosin Y and Ervthrosine Uptake in Cancer Cells
BXPC3 and H460 cells were seeded in a 96 well plate; 4x103 cells per well in ΙΟΟμΙ-, of RPMI medium containing 10% FBS. The cells were then incubated for approximately 24 hours before addition of nanoemulsion. The media was removed, and 50μΙ_- of Eosin Y and Erythrosine-containing nanoemulsion at a concentration of 300mg/L was added to the cells and incubated for 45 minutes. The nanoemulsion added to the cells were made by Dr. Frank Gibson of Cornerstone Pharmaceuticals, Inc., Cranbury, NJ. The cells were then washed three times in PBS, and the uptake of Eosin Y and Erythrosine-containing nanoemulsion was determined by measuring the fluorescence at excitation/emission wavelengths of 485/520 and 544/590nm using the FLUOstar OPTIMA plate reader.
Results
Eosin Y and Ervthrosine Uptake in Cancer Cells.
As seen in Tables 1 and 2, a significant uptake of Eosin Y-containing nanoemulsion was seen within 45 minutes of treatment in both BXPC3 and H460 cancer cells as compared to that of Erythrosine, which demonstrated much smaller uptake. The control values of Eosin Y and Erythrosine fluorescence without cellular uptake is presented in Table 3.
Table 1. Fluorescence at Excitation/emission Wavelengths of 485/520nm
Cells were treated with Eosin Y and Erythrosine-containing nanoemulsion, and the fluorescence was measured at excitation/emission wave lengths of 485/520nm. The average fluorescence was calculated by taking the mean of five replicates.
Table 2. Fluorescence at Excitation/emission Wavelengths of 544/590nm
Cells were treated with Eosin Y and Erythrosine-containing nanoemulsion, and the fluorescence was measured at excitation/emission wave lengths of 544/590nm. The average fluorescence was calculated by taking the mean of five replicates.
Table 3. Fluorescence of Eosin Y and Erythrosine Solutions in the Absence of Cancer Cells
Eosin Y and Erythrosine-containing nanoemulsion was added to a 96-well plate, and the fluorescence was measured at excitation/emission wavelengths of 485/520 and 544/590nm. The average fluorescence was calculated by taking the mean of five replicates.
Conclusion
The excitation/emission wavelengths of Eosin Y are 525/545nm and the excitation/emission wavelengths of Erythrosine are 530/558nm. Under the conditions tested, Eosin Y-containing nanoemulsion showed higher uptake inside the cells at both wavelength ranges tested, compared to Erythrosine-containing nanoemulsion. Overall, given this higher cellular uptake, it is suggested that the measurement of Eosin Y fluorescence in cancer cells at excitation/emission wavelengths of 485/520nm would provide a good system to study the uptake of the lipid-oil-water nanoemulsion of the present invention in cancer cells.
EXAMPLE 2
CELLULAR UPTAKE OF FLUORESCENT-TAGGED LIPID-OIL-WATER
NANOP ARTICLES
Summary
The studies described in this section were performed in order to determine if human tumor cells take up BODIPY-labelled lipid-oil-water nanoemulsion (LN) preparations and if they display differential ability to take up LN. It was found that most tumor cell lines tested took up fluorescent LN readily. It was also observed that tumor cell lines from different tumor cell lineages displayed differential ability to take up LN.
Materials and Methods
Preparation of LN Formulation
The LN formulation used for these experiments was prepared as follows: non-polar lipids were solubilized in 95% ethanol to lOmg/mL by sonication for 10 minutes. ΙΟΟμΙ. of 0.5mg/mL cholesteryl BODIPY-FL (Molecular Probes, Eugene, OR) in ethanol was added to lmL of the lOmg/mL solubilized lipids.
The lipid and cholesteryl BODIPY-FL mixture was added to 50mL of a solution of ImM sodium pyrophosphate in water and processed through a Microfluidics microfluidizer model 110Y (Microfluidics, Inc., Newton, MA).
Assay of fluorescent LN uptake by fluorescence-activated cell sorting (FACS)
In order to first establish that extent of cell uptake of fluorescent LN is directly proportional to cell fluorescence intensity on FACS, 200μg/mL LN were labelled with 2^g/mL of the fluorescent lipophilic dye DiO (Molecular Probes, Eugene, OR), which can be detected using filter sets for fluorescein, by microfluidization. Labelled LN was added to 0, 12.5, 25, 50, and 100μg/mL C6 cells and incubated at 37°C for 60 minutes, after which media was removed, the cells washed with PBS, trypsinized, washed again before fixation in 4% formaldehyde. In an additional experiment, 50μg/mL DiO-labelled LN was added to cells and incubated for 0, 5, 10,15, 30, and 60 minutes before removal of media and processing for FACS analysis. As seen in FIGURE 1 , average fluorescence intensity per cell is directly proportional to concentration of LN; furthermore, as seen in FIGURE 2, average fluorescence intensity per cell is also directly proportional to time of incubation in the presence of LN. These experiments were visually confirmed by the finding that fluorescence intensity was proportional to extent of fluorescent LN uptake with identically treated cells
fixed on glass coverslips (data not shown). Overall, these results suggest that LN uptake can be assessed by FACS.
Uptake of LN by tumor cell lines from diverse tumor lineages
In order to determine if cells from different cell lineages display differential ability to take up LN and also to assess relative abilities of cells from different tumor types to take up LN, LN was prepared with 20(^g/mL lipids and 0.5% w/w cholesteryl-BODIPY-FL, by microfluidization. The cell lines chosen for analysis were HS-578T, MDA-MB-231, and MX-1 breast cancer, H23, H460, and H522 lung cancer, SF-539 glioblastoma, and HT29, SW-620, and COLO205 colon tumor cell lines. These cell lines were selected from those used by the National Cancer Institute (NCI)'s Developmental Therapeutics Program In Vitro Screening, which consists of cell lines representing different tumor types and derived from a number of different human tumor lineages.
Labelled LN was added to cells and incubated at 37°C, after which media was removed, the cells washed with PBS, trypsinized, washed again before fixation in 0.4% formaldehyde. Samples were analyzed by FACS and average fluorescence intensity per cell was determined. Average fluorescence intensity per cell for the colon, breast, central nervous system (CNS), and lung cell lines were compared to those of HT-29 colon carcinoma cell line and SF-539 glioblastoma cancer cell line, since these had been established through repeated experiments to take up low and high quantities of fluorescent LN, respectively. Fluorescent LN uptake by each LN-treated cell sample was obtained by subtracting the fluorescence intensity from the same cell line, which had been untreated.
Upon comparison of LN uptake by cell lines from the NCI panel, as seen graphically in FIGURES 3 through 6 and also in Table 4, it was found that LN uptake varies among cell types of different lineages. Although some variability was seen among cells from the same
tumor lineage, relative uptake was fairly consistent for each tumor lineage. For example, as is evident from FIGURES 3, 4, and 6, breast and lung tumor cell lines generally display higher LN uptake than did colon tumor cell lines. Overall, upon comparison, it is evident that the greatest LN uptake is observed in cell lines from liver and uterine tumors (Table 4), lung tumors (FIGURE 6), and CNS tumors (FIGURE 5).
Table 4. Uptake of LN by Tumor Cell
Tumor cell type Relative cell uptake of fluorescent LN
Tumor cell lineage Cell line Fluorescence intensity per cell Sample via FACS § (mean ± SEM) size
MDA-MB-231 120.02 ± 26.37 4
Breast HS578T 100.65 ± 12.48 4
MX-1 86.51 ± 13.28 3
H460 93.60 ± 20.34 5
A549 48.82 ± 8.07 4
Lung
H23 189.03 ± 37.86 4
H522 184.67 ± 40.58 4
SF-539 219.63 ± 23.33 10
Central nervous SF-268 100.41 ± 7.17 3 system SF-295 232.74 ± 45.79 2
U-87 234.07 ± 25.54 2
HT-29 46.44 ± 5.68 12
COLO-205 35.17 ± 6.89 4
Colon SW-620 32.1 1 ± 7.79 4
HCT-15 31.59 ± 16.66 3
Caco-2 52.87 ± 5.52 4
Liver Hep-3B 537.69 ± 27.71 7
MES-SA 204.92 ± 39.38 4
Uterine and drug- resistant uterine MES-SA-DX5 180.57 ± 27.88 4
MES-SA-MX2 220.81 ± 32.85 6
Ovarian SKOV-3 65.81 ± 1 1.42 4
PAN 02 21 1.99 ± 35.76 4
Pancreatic
PAN 03 73.07 ± 22.3£ 4 δ Average fluorescence intensity per cell was obtained for each fluorescent LN-treated sample, by comparing and subtracting fluorescence from the same respective untreated cell line.
ND- Not determined. Particle diameter not determinable because of high level of precipitation.
It will be understood that the present invention is directed to a delivery system in the form of a composition for delivering imaging and/or therapeutic agents, including anticancer agents, for treating cancerous cells and tissues. Accordingly, all anticancer agents are within the scope of the present invention, as well as all diseased tissues and cells exhibiting cellular hyperproliferation and aberrant lipid metabolism and elevated uptake of lipids, including cancer cells, which may be imaged and/or treated by such agents.
The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying claims, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims. Furthermore, while exemplary embodiments have been expressed herein, others practiced in the art may be aware of other designs or uses of the present invention. Thus, while the present invention has been described in connection with exemplary embodiments thereof, it will be understood that many modifications in both design and use will be apparent to those of ordinary skill in the art, and this application is intended to cover any adaptations or variations thereof. It is therefore manifestly intended that this invention be limited only by the claims and the equivalents thereof.
Claims
1. A stable lipid-oil-water nanoemulsion useful for selectively and preferentially imaging a diseased, injured, or injuriously mutated tissue, cell, or at least one organelle thereof.
2. The nanoemulsion of claim 1 , wherein the tissue, cell, or at least one organelle thereof, is found in a warm-blooded animal, including humans.
3. The nanoemulsion of claim 1 , wherein the nanoemulsion comprises:
a lipid-oil-water nanoemulsion containing at least one non-bilayer-forming lipid, or analog thereof, capable of being preferentially and selectively concentrated on or within a diseased, injured, or mutated tissue, cell, or at least one organelle thereof;
an effective amount of at least one pharmaceutically-acceptable imaging agent encapsulated within, incorporated into, or associated with the nanoemulsion;
and a pharmaceutically-acceptable carrier or excipient therefor,
wherein said nanoemulsion is produced by processing through homogenization and sterilization.
4. The nanoemulsion of claim 3, wherein the sterilization is accomplished through use of radiation, solvents, endotoxin removal means, or pasteurization.
5. The nanoemulsion of claim 3, wherein the at least one non-bilayer-forming lipid, or analog thereof, may be of imaging benefit.
6. The nanoemulsion of claim 1 , wherein the diseased, injured, or injuriously mutated cells exhibit changes in lipid processing.
7. The nanoemulsion of claim 6, wherein the disease, condition or syndrome is characterized by cellular hyperproliferation.
8. The nanoemulsion of claim 7, wherein the cells are capable of forming tumors.
9. The nanoemulsion of claim 8, wherein the cells are malignant.
10. The nanoemulsion of claim 3, wherein the effective amount of the imaging agent is sufficient to generate an image of the tissue, cell, or at least one organelle thereof.
1 1. The nanoemulsion of claim 3, wherein the imaging agent also has therapeutic capability.
12. The nanoemulsion of claim 3, wherein the imaging agent is radioactive.
13. The nanoemulsion of claim 12, wherein the imaging agent contains a radioisotope, such as but not limited to bismuth-213, carbon-11, carbon-14, cesium-137, chromium-51, cobalt-57, cobalt-60, copper-64, dysprosium- 165, erbium-169, fluorine-18, gallium-67, gold-198, holmium-166, indium-I l l, iodine-123, iodine-125, iodine-131, iridium-192, iron-59, krypton-81m, lutetium-177, molybdenum-99, nitrogen-13, oxygen-15, palladium- 103, phosphorus-32, potassium-42, rhenium- 186, rhenium- 188, rubidium-81, rubidium-82, ruthenium- 106, samarium-153, selenium-75, sodium-24, strontium-89, strontium-92, technetium-99m, thallium-201, xenon-133, ytterbium- 169, and yttrium-90.
14. The nanoemulsion of claim 3, wherein the imaging agent is activated by an external energy source, such as but not limited to light, heat, ultrasound, and x-rays.
15. The nanoemulsion of claim 3, wherein the imaging agent is detectable upon administration to the tissue or cell.
16. The nanoemulsion of claim 15, wherein the imaging agent is colored within the visible spectrum.
17. The nanoemulsion of claim 3, wherein the imaging agent fluoresces or can be induced to fluoresce.
18. The nanoemulsion of claim 17, wherein the imaging agent is DiO, BODIPY, eosin Y, or erythrosine B.
19. The nanoemulsion of claim 1, wherein the imaging agent is an imageable sterol.
20. The nanoemulsion of claim 19, wherein the imageable sterol is imageable cholesterol or an analog thereof.
21. The nanoemulsion of claim 20, wherein the imageable cholesterol or an analog thereof is radioactive.
22. The nanoemulsion of claim 20, wherein the imageable cholesterol is
BODIPY-cholesterol.
23. The nanoemulsion of claim 20, wherein the imageable cholesterol is NBD- cholesterol.
24. The nanoemulsion of claim 20, wherein the imageable cholesterol is dansyl- cholesterol.
25. The nanoemulsion of claim 20, wherein the imageable sterol is labelled cholesteryl ester.
26. The nanoemulsion of claim 1, wherein the imaging agent is a complex metal suitable for imaging by one or more contrast imaging modalities.
27. The nanoemulsion of claim 26, wherein the complex metal is, without limitation, chromium, copper, dysprosium, europium, gadolinium, gold, iron, manganese, or zinc.
28. The nanoemulsion of claim 1, wherein the nanoemulsion is taken up into the cell in an endosome.
29. The nanoemulsion of claim 28, wherein the endosome is taken up actively.
30. The nanoemulsion of claim 29, wherein the endosome is taken up by phagocytosis or pinocytosis.
31. The nanoemulsion of claim 29, wherein the endosome is taken up passively.
32. The nanoemulsion of claim 29, wherein the endosome is degraded upon cellular uptake such that the imaging agent is distributed within the cell.
33. The nanoemulsion of claim 3, where the non-bilayer forming lipid forms lipid particles.
34. The nanoemulsion of claim 33, wherein the lipid particles are comprised of a mixture of non-bilayer forming-lipids.
35. The nanoemulsion of claim 34, wherein the lipid particles are present in an amount of from about 0.1 μg/mL to 1000 μ^πιΐί,.
36. The nanoemulsion of claim 35, wherein the lipid particles are present in an amount of from about 10 g/mL to 800 μ^πιΐ^.
38. The nanoemulsion of claim 33, wherein the average particle size of the lipid particles is up to 0.2 μιη.
39. The nanoemulsion of claim 38, wherein the average particle size of the lipid particles is from about 0.02 to 0.2 μηι.
40. The nanoemulsion of claim 3, wherein the non-bilayer-forming lipid is no more than weakly polar.
41. The nanoemulsion of claim 40, wherein the non-bilayer-forming lipid is substantially non-polar or neutral.
42. The nanoemulsion of claim 41, wherein the non-bilayer-forming lipid is neutral.
43. The nanoemulsion of claim 1, wherein the nanoemulsion is stably dispersed in an aqueous phase for at least seven days.
44. The nanoemulsion of claim 43, wherein the nanoemulsion is stably dispersed in an aqueous phase for at least fourteen days.
45. The nanoemulsion of claim 44, wherein the nanoemulsion is stably dispersed in an aqueous phase for at least one month.
46. The nanoemulsion of claim 45, wherein the nanoemulsion is stably dispersed in an aqueous phase for at least six months.
47. The nanoemulsion of claim 46, wherein the nanoemulsion is stably dispersed in an aqueous phase for at least one year.
48. The nanoemulsion of claim 3, further comprising emulsion-enhancing agents.
49. The nanoemulsion of claim 48, wherein the emulsion-enhancing agents are selected from the group consisting of a surfactant, a plant-based fat source, a solvent, and combinations thereof.
50. The nanoemulsion of claim 49, wherein the surfactant is a non-ionic surfactant.
51. The nanoemulsion of claim 50, wherein the non-ionic surfactant may be linear or branch-chained.
52. The nanoemulsion of claim 50, wherein the non-ionic surfactant may be of uniform composition.
53. The nanoemulsion of claim 50, wherein the non- ionic surfactant may be derived from co-polymers.
54. The nanoemulsion of claim 53, wherein the polymers have a molecular weight between 500 and 7500.
55. The nanoemulsion of claim 54, wherein the polymers have a molecular weight between 1000 and 5000.
56. The nanoemulsion of claim 55, wherein the polymers have a molecular weight between 1200 and 4000.
57. The nanoemulsion of claim 53, wherein the polymers form an intracellular scaffold susceptible to enzymatic or environmental condition-based cleavage within the cell or at least one organelle thereof.
58. The nanoemulsion of claim 50, wherein the non-ionic surfactant is a detergent polysorbate.
59. The nanoemulsion of claim 58, wherein the detergent polysorbate is Tween®-
80.
60. The nanoemulsion of claim 50, wherein the non-ionic surfactant is a sorbitan ester.
61. The nanoemulsion of claim 60, wherein the sorbitan ester is selected from the group consisting of fatty-acylated sorbitan esters and polyoxyethylene derivatives thereof, and mixtures thereof.
62. The nanoemulsion of claim 50, wherein the surfactant is present in an amount sufficient to prevent the nanoemulsion from deteriorating in storage.
63. The nanoemulsion of claim 62, wherein the surfactant is present in amounts of from about 0.01% w/v to 4.0% w/v.
64. The nanoemulsion of claim 63, wherein the surfactant is present in amounts of from about 0.1% w/v to 3.0% w/v.
65. The nanoemulsion of claim 50, wherein the solvent is a water-miscible solvent.
66. The nanoemulsion of claim 65, wherein the water-miscible solvent is selected from the group consisting of a polar solvent and combinations thereof.
67. The nanoemulsion of claim 66, wherein the solvent is selected from the group consisting of a polar aprotic solvent, a polar protic solvent, and combinations thereof.
68. The nanoemulsion of claim 67, wherein the polar aprotic solvent is dimethyl sulfoxide or dimethylamine.
69. The nanoemulsion of claim 67, wherein the polar protic solvent is an alcohol.
70. The nanoemulsion of claim 69, wherein the alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, benzyl alcohol, and combinations thereof.
71. The nanoemulsion of claim 50, wherein the solvent is present in an amount sufficient to control the extent of aggregation of the surfactant.
72. The nanoemulsion of claim 71, wherein the solvent is present in amounts of from about 0.001% v/v to 99.9% v/v.
73. The nanoemulsion of claim 72, wherein the solvent is present in amounts of from about 0.005% v/v to 80% v/v.
74. The nanoemulsion of claim 50, wherein the plant-based fat source is produced or derived from natural sources.
75. The nanoemulsion of claim 50, wherein the plant-based fat source is produced or derived by chemical means.
76. The nanoemulsion of claim 50, wherein the plant-based fat source is produced or modified by recombinant means.
77. The nanoemulsion of claim 50, wherein the plant-based fat source is suitably stable for pharmaceutical use at room temperature.
78. The nanoemulsion of claim 77, wherein the nanoemulsion is stable at room temperature for at least one month.
79. The nanoemulsion of claim 78, wherein the nanoemulsion is stable at room temperature for at least six months.
80. The nanoemulsion of claim 79, wherein the nanoemulsion is stable at room temperature for at least one year.
81. The nanoemulsion of claim 50, wherein the plant-based fat source is suitably stable for pharmaceutical use upon storage in a refrigerator.
82. The nanoemulsion of claim 81, wherein the nanoemulsion is stable in storage for at least three days.
83. The nanoemulsion of claim 82, wherein the nanoemulsion is stable in storage for at least one month.
84. The nanoemulsion of claim 83, wherein the nanoemulsion is stable in storage for at least six months.
85. The nanoemulsion of claim 84, wherein the nanoemulsion is stable in storage for at least one year.
86. The nanoemulsion of claim 50, wherein the plant-based fat source is suitably stable for pharmaceutical use upon storage in a freezer.
87. The nanoemulsion of claim 86, wherein the nanoemulsion is stable in storage for at least one week.
88. The nanoemulsion of claim 87, wherein the nanoemulsion is stable in storage for at least one month.
89. The nanoemulsion of claim 88, wherein the nanoemulsion is stable in storage for at least six months.
90. The nanoemulsion of claim 89, wherein the nanoemulsion is stable in storage for at least one year.
91. The nanoemulsion of claim 50, wherein the plant-based fat source is vegetable oil.
92. The nanoemulsion of claim 91, wherein the vegetable oil is, without limitation, soybean oil, flaxseed oil, hemp oil, linseed oil, mustard oil, rapeseed oil, canola oil, safflower oil, sesame oil, sunflower oil, grape seed oil, almond oil, apricot oil, castor oil, corn oil, cottonseed oil, coconut oil, hazelnut oil, neem oil, olive oil, palm oil, palm kernel oil, peanut oil, pumpkin seed oil, rice bran oil, walnut oil, and combinations and/or specific fractions thereof.
93. The nanoemulsion of claim 91, wherein the vegetable oil is leguminous.
94. The nanoemulsion of claim 93, wherein the vegetable oil is soybean oil.
95. The nanoemulsion of claim 50, wherein the plant-based fat source is present in an amount sufficient to permit higher surface tension in the nanoemulsion, thereby increasing the probability of hydrophobic interactions with the plasma membrane of a target cell.
96. The nanoemulsion of claim 95, wherein the plant-based fat source is present in amounts of from about 0.001% v/v to 5.0% v/v.
97. The nanoemulsion of claim 96, wherein the plant-based fat source is present in amounts of from about 0.005% v/v to 4.0% v/v.
98. The nanoemulsion of claim 3, wherein the at least one non-bilayer-forming lipid is selected from the group consisting of glycerol monoesters of carboxylic acids, aliphatic alcohols, sterol aromatic acid esters, sterols, terpenes, bile acids, alkali metal salts of bile acid, sterol esters of aliphatic acids, sterol esters of sugar acids, esters of sugar acids, esters of aliphatic alcohols, esters of sugars, esters of aliphatic acids, sugar acids, saponins, sapogenins, glycerol, glycerol di-esters of aliphatic acids, glycerol tri-esters of aliphatic acids, glycerol di-esters of aliphatic alcohols, and glycerol tri-esters of aliphatic alcohols, and combinations thereof.
99. The nanoemulsion of claim 3, wherein the at least one non-bilayer-forming lipid is in the form of a lipid mixture comprising:
a) at least one first member selected from the group consisting of glycerol monoesters of carboxylic acids containing from about 9 to 18 carbon atoms and aliphatic alcohols containing from about 10 to 18 carbon atoms;
b) at least one second member selected from the group consisting of sterol aromatic acid esters; and c) at least one third member selected from the group consisting of sterols, terpenes, bile acids and alkali metal salts of bile acids.
100. The nanoemulsion of claim 99, wherein the glycerol monoesters of carboxylic acids are saturated.
101. The nanoemulsion of claim 99, wherein the glycerol monoesters of carboxylic acids are unsaturated.
102. The nanoemulsion of claim 99, wherein the lipid mixture has a weight ratio of (a):(b):(c) of (l-5):(0.25-3):(0.25-3) based on the total weight of the nanoemulsion.
103. The nanoemulsion of claim 99, wherein the lipid mixture further comprises: d) at least one fourth member selected from the group consisting of sterol esters of aliphatic acids containing from about 1 to 18 carbon atoms; sterol esters of sugar acids; esters of sugar acids and aliphatic alcohols containing from about 10 to 18 carbon atoms; esters of sugars and aliphatic acids containing from about 10 to 18 carbon atoms; sugar acids, saponins; and sapogenins; and
e) at least one fifth member selected from the group consisting of glycerol; glycerol di- and tri-esters of aliphatic acids containing from about 10 to 18 carbon atoms; and aliphatic alcohols containing from about 10 to 18 carbon atoms.
104. The nanoemulsion of claim 103, wherein the lipid mixture has a weight ratio of (a):(b):(c):(d):(e) of (l-5):(0.25-3):(0.25-3):(0.25-3):(0.25-3) based on the total weight of the nanoemulsion.
105. The nanoemulsion of claim 3, wherein the nanoemulsion or the imaging agent acts a ligand.
106. The nanoemulsion of claim 3, wherein the nanoemulsion or the imaging agent acts as a ligand binding agent.
107. The nanoemulsion of claim 103 or 104, wherein the target cell is detectable by immunofluorescence.
108. The nanoemulsion of claim 1, wherein the nanoemulsion acts as a biomarker for diseased, injured, or mutated tissue, cells, and/or at least one organelle thereof, that are amenable to delivery of the imaging agent by the nanoemulsion.
109. A method of preparing the nanoemulsion of claim 3, comprising the steps of: a) mixing the at least one non-bilayer-forming lipid with an effective amount of at least one imaging agent to yield a lipid portion;
b) adding the lipid portion to an aqueous phase to yield a dispersion; and
c) agitating the dispersion under high-shear conditions to sufficiently disperse the at least one non-bilayer-forming lipid therethrough to form a lipid nanoemulsion comprised of lipid particles.
110. The method of claim 109, further comprising the step of adding an emulsion- enhancing agent to the nanoemulsion.
111. The method of claim 110, wherein the emulsion-enhancing agent is selected from the group consisting of a surfactant, a solvent, a plant-based fat source, and combinations and/or specific fractions thereof.
112. The method of claim 111, further comprising the step of mixing the surfactant with the at least one non-bilayer-forming lipid prior to the step of mixing with the imaging agent.
113. The method of claim 111, further comprising the step of mixing the plant- based fat source with the at least one non-bilayer-forming lipid prior to the step of mixing with the imaging agent.
114. The method of claim 111, further comprising the step of mixing the solvent with the imaging agent prior to the step of mixing with the at least one non-bilayer forming lipid.
115. The method of claim 109, wherein the agitating step comprises processing the lipid mixture by a fluid homogenization process.
116. The method of claim 115, wherein the fluid homogenization process is selected from the group consisting of high-shear homogenization, ultrasound homogenization, high-pressure homogenization, membrane extrusion, sonication, fluidization, and combinations thereof.
117. The method of claim 109, further comprising sterilizing the nanoemulsion.
118. The method of claim 1 17, wherein the sterilization is accomplished through use of radiation, solvents, endotoxin removal means, or pasteurization.
119. The method of claim 109, further comprising processing the nanoemulsion by aseptic filtration.
120. The method of claim 119, wherein the processing step comprises passing the nanoemulsion through a 0.2 μη membrane.
121. The method of claim 109, wherein the imaging agent is complexed, conjugated, or otherwise rendered lipophilic to facilitate lipid portion formation.
122. A method of imaging a diseased, injured, or injuriously mutated cell or tissue, or at least one organelle thereof, comprising administering to the animal an effective amount of the nanoemulsion of claim 1 and performing an imaging procedure thereupon.
123. The method of claim 122, wherein the imaging procedure is performed in vivo.
124. The method of claim 123, further comprising surgical resection of diseased tissue upon delineation of the boundaries of the diseased tissue after performance of the imaging procedure.
125. The method of claim 124, further comprising performance of image-guided radiation therapy.
126. The method of claim 122, wherein the imaging procedure is performed after biopsy of a sample containing the cell.
127. The method of claim 122, wherein the imaging procedure is x-ray imaging.
128. The method of claim 122, wherein the imaging procedure is magnetic resonance imaging.
129. The method of claim 122, wherein the imaging procedure is computer-aided tomography.
130. The method of claim 122, wherein the imaging procedure is positron emission tomography.
131. The method of claim 122, wherein the imaging procedure is immunofluorescence .
132. The method of claim 122, wherein the disease, injury, or injurious mutation includes changes in lipid processing.
133. The method of claim 132, wherein the cell is capable of forming tumors.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/000314 WO2011102906A1 (en) | 2010-02-19 | 2011-02-22 | Imageable lipid-oil-water nanoemulsion delivery system |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21248810P | 2010-02-19 | 2010-02-19 | |
US61/212,488 | 2010-02-19 | ||
PCT/US2011/000314 WO2011102906A1 (en) | 2010-02-19 | 2011-02-22 | Imageable lipid-oil-water nanoemulsion delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011102906A1 true WO2011102906A1 (en) | 2011-08-25 |
Family
ID=44838183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/000314 WO2011102906A1 (en) | 2010-02-19 | 2011-02-22 | Imageable lipid-oil-water nanoemulsion delivery system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011102906A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
WO2019246632A1 (en) * | 2018-06-22 | 2019-12-26 | The Regents Of The University Of Colorado A Body Corporate | Use of cannabinoids to increase the lipid order of cell membranes |
CN114177194A (en) * | 2021-11-13 | 2022-03-15 | 广东暨创硒源纳米研究院有限公司 | NK cell sensitizer prepared by combining functionalized nano-selenium with metformin and application |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020155084A1 (en) * | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
US20030026831A1 (en) * | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
US20030077329A1 (en) * | 2001-10-19 | 2003-04-24 | Kipp James E | Composition of and method for preparing stable particles in a frozen aqueous matrix |
US20030175205A1 (en) * | 2000-04-12 | 2003-09-18 | Kent Jorgensen | Lipid-based systems for targeting diagnostic agents |
US20040170565A1 (en) * | 1998-10-12 | 2004-09-02 | Cantrell Gary L. | Novel ultrasound contrast agents |
US20050079131A1 (en) * | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
US20060240092A1 (en) * | 2005-04-01 | 2006-10-26 | Kurt Breitenkamp | Polymeric micelles for drug delivery |
US20060258933A1 (en) * | 2005-05-10 | 2006-11-16 | Advanced Clinical Solutions, Inc. | Method of defining a biological target for treatment |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
US20080177059A1 (en) * | 2007-01-12 | 2008-07-24 | Robert Bittman | Free cholesterol analogs bearing a boron dipyrromethene difluoro (bodipy) fluorophore in the side chain and method of preparation and use thereof |
US20080247987A1 (en) * | 2005-08-04 | 2008-10-09 | Angiotech International Ag | Block Copolymer Compositions and Uses Thereof |
US20080317799A1 (en) * | 2007-05-02 | 2008-12-25 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20090247608A1 (en) * | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
-
2011
- 2011-02-22 WO PCT/US2011/000314 patent/WO2011102906A1/en active Application Filing
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040170565A1 (en) * | 1998-10-12 | 2004-09-02 | Cantrell Gary L. | Novel ultrasound contrast agents |
US20030175205A1 (en) * | 2000-04-12 | 2003-09-18 | Kent Jorgensen | Lipid-based systems for targeting diagnostic agents |
US20020155084A1 (en) * | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
US20030026831A1 (en) * | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
US20030077329A1 (en) * | 2001-10-19 | 2003-04-24 | Kipp James E | Composition of and method for preparing stable particles in a frozen aqueous matrix |
US20070128117A1 (en) * | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
US20050079131A1 (en) * | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
US20060240092A1 (en) * | 2005-04-01 | 2006-10-26 | Kurt Breitenkamp | Polymeric micelles for drug delivery |
US20060258933A1 (en) * | 2005-05-10 | 2006-11-16 | Advanced Clinical Solutions, Inc. | Method of defining a biological target for treatment |
US20080247987A1 (en) * | 2005-08-04 | 2008-10-09 | Angiotech International Ag | Block Copolymer Compositions and Uses Thereof |
US20080177059A1 (en) * | 2007-01-12 | 2008-07-24 | Robert Bittman | Free cholesterol analogs bearing a boron dipyrromethene difluoro (bodipy) fluorophore in the side chain and method of preparation and use thereof |
US20080317799A1 (en) * | 2007-05-02 | 2008-12-25 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20090247608A1 (en) * | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
WO2019246632A1 (en) * | 2018-06-22 | 2019-12-26 | The Regents Of The University Of Colorado A Body Corporate | Use of cannabinoids to increase the lipid order of cell membranes |
CN114177194A (en) * | 2021-11-13 | 2022-03-15 | 广东暨创硒源纳米研究院有限公司 | NK cell sensitizer prepared by combining functionalized nano-selenium with metformin and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy | |
CN104023793B (en) | Joint liposome composition for treating cancer | |
Ganta et al. | Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer | |
Su et al. | Analytical methods for investigating in vivo fate of nanoliposomes: A review | |
Sloat et al. | In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles | |
Wang et al. | GLP-1R–targeting magnetic nanoparticles for pancreatic islet imaging | |
EP2229411B1 (en) | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles | |
He et al. | Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy | |
Kluza et al. | Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity | |
US20220218827A1 (en) | Delivery of therapeutic compounds with iron oxide nanoparticles | |
US20080253960A1 (en) | Lipoprotein-Based Nanoplatforms | |
Lee et al. | Modular Polymer-Caged Nanobins as a Theranostic Platform with Enhanced Magnetic Resonance Relaxivity and pH-Responsive Drug-Release | |
Bye et al. | Nitroxide-loaded hexosomes provide MRI contrast in vivo | |
Charron et al. | Theranostic lipid nanoparticles for cancer medicine | |
US9844656B2 (en) | Localization of agents at a target site with a composition and an energy source | |
Maranhao et al. | Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients | |
Skupin-Mrugalska et al. | Theranostic liposomes as a bimodal carrier for magnetic resonance imaging contrast agent and photosensitizer | |
Zhou et al. | Charge-switchable nanocapsules with multistage pH-responsive behaviours for enhanced tumour-targeted chemo/photodynamic therapy guided by NIR/MR imaging | |
Sang et al. | CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer | |
Liu et al. | Theranostic polymeric micelles for the diagnosis and treatment of hepatocellular carcinoma | |
CN108430520A (en) | Long-acting gadolinium base cancer target imaging and therapeutic agent | |
Aryasomayajula et al. | Multifunctional liposomes | |
Liu et al. | The combined therapeutic effects of 131iodine-labeled multifunctional copper sulfide-loaded microspheres in treating breast cancer | |
Hua et al. | Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo-and chemotherapy | |
Xing et al. | Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11745004 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11745004 Country of ref document: EP Kind code of ref document: A1 |